Table 2: Updated MIPS Benchmark Results Using FS PY2018 Logic,,,,,,,,,,,,,
,,,,,,,,,,,,,
Measure_Name,Measure_ID,Submission_Method,Measure_Type,Benchmark,Decile_3,Decile_4,Decile_5,Decile_6,Decile_7,Decile_8,Decile_9,Decile_10,TOPPED_OUT
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,EHR,IntermediateOutcome,Y,92.62 - 74.49,74.48 - 59.10,59.09 - 46.87,46.86 - 37.91,37.9 - 31.42,31.41 - 26.06,26.05 - 20.94,<= 20.93,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Registry/QCDR,IntermediateOutcome,Y,90.32 - 71.44,71.43 - 56.83,56.82 - 42.68,42.67 - 32.52,32.51 - 24.82,24.81 - 19.01,19.0 - 13.34,<= 13.33,No
Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%),1,Claims,IntermediateOutcome,Y,45.64 - 26.93,26.92 - 18.76,18.75 - 14.76,14.75 - 11.68,11.67 - 9.10,9.09 - 7.01,7.0 - 4.56,<= 4.55,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,Registry/QCDR,Process,Y,68.52 - 78.86,78.87 - 84.74,84.75 - 90.15,90.16 - 94.35,94.36 - 97.36,97.37 - 99.35,99.36 - 99.99,100.00,No
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD),5,EHR,Process,Y,59.55 - 68.96,68.97 - 73.99,74.0 - 77.26,77.27 - 80.47,80.48 - 83.32,83.33 - 86.45,86.46 - 89.99,>= 90.0,No
Coronary Artery Disease (CAD): Antiplatelet Therapy,6,Registry/QCDR,Process,Y,74.76 - 83.36,83.37 - 88.23,88.24 - 91.29,91.3 - 93.74,93.75 - 95.70,95.71 - 97.55,97.56 - 99.99,100.00,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,EHR,Process,Y,70.76 - 78.12,78.13 - 81.81,81.82 - 84.61,84.62 - 86.73,86.74 - 88.70,88.71 - 90.59,90.6 - 92.58,>= 92.59,No
Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%),7,Registry/QCDR,Process,Y,82.76 - 87.95,87.96 - 90.36,90.37 - 92.58,92.59 - 94.19,94.2 - 95.51,95.52 - 96.96,96.97 - 98.56,>= 98.57,No
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,EHR,Process,Y,70.0 - 78.98,78.99 - 83.86,83.87 - 87.17,87.18 - 89.54,89.55 - 91.52,91.53 - 93.47,93.48 - 95.23,>= 95.24,No
Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD),8,Registry/QCDR,Process,Y,85.71 - 91.29,91.3 - 94.43,94.44 - 95.82,95.83 - 97.24,97.25 - 98.43,98.44 - 99.99,--,100.00,No
Anti-Depressant Medication Management,9,EHR,Process,Y,18.25 - 28.43,28.44 - 37.03,37.04 - 44.07,44.08 - 49.35,49.36 - 53.29,53.3 - 59.77,59.78 - 77.67,>= 77.68,No
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,012,Registry/QCDR,Process,Y,84.42 - 94.57,94.58 - 98.31,98.32 - 99.51,99.52 - 99.99,--,--,--,100.00,Yes
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,012,EHR,Process,Y,66.67 - 81.24,81.25 - 87.19,87.2 - 91.06,91.07 - 93.91,93.92 - 95.89,95.9 - 97.64,97.65 - 98.79,>= 98.8,Yes
Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation,012,Claims,Process,Y,97.37 - 99.99,--,--,--,--,--,--,100.00,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,014,Registry/QCDR,Process,Y,60.77 - 81.84,81.85 - 90.31,90.32 - 94.41,94.42 - 96.92,96.93 - 98.58,98.59 - 99.61,99.62 - 99.99,100.00,Yes
Age-Related Macular Degeneration (AMD): Dilated Macular Examination,014,Claims,Process,Y,92.31 - 99.99,--,--,--,--,--,--,100.00,Yes
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy,018,EHR,Process,Y,53.46 - 73.58,73.59 - 83.47,83.48 - 89.28,89.29 - 93.24,93.25 - 95.69,95.7 - 97.49,97.5 - 98.90,>= 98.91,No
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,Claims,Process,Y,99.35 - 99.99,--,--,--,--,--,--,100.00,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,Registry/QCDR,Process,Y,38.78 - 74.18,74.19 - 87.61,87.62 - 93.87,93.88 - 98.64,98.65 - 99.99,--,--,100.00,Yes
Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care,019,EHR,Process,Y,35.5 - 58.49,58.5 - 71.06,71.07 - 80.14,80.15 - 86.50,86.51 - 91.33,91.34 - 95.23,95.24 - 98.00,>= 98.01,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second-Generation Cephalosporin,021,Registry/QCDR,Process,Y,56.88 - 94.33,94.34 - 98.97,98.98 - 99.99,--,--,--,--,100.00,Yes
Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second-Generation Cephalosporin,021,Claims,Process,Y,94.59 - 99.99,--,--,--,--,--,--,100.00,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),023,Claims,Process,Y,98.39 - 99.99,--,--,--,--,--,--,100.00,Yes
Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients),023,Registry/QCDR,Process,Y,79.67 - 96.05,96.06 - 99.40,99.41 - 99.99,--,--,--,--,100.00,Yes
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,024,Registry/QCDR,Process,Y,12.29 - 25.02,25.03 - 52.79,52.8 - 69.06,69.07 - 76.96,76.97 - 87.87,87.88 - 95.83,95.84 - 99.93,>= 99.94,Yes
Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older,024,Claims,Process,Y,54.84 - 87.09,87.1 - 95.91,95.92 - 97.29,97.3 - 99.34,99.35 - 99.99,--,--,100.00,Yes
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,Registry/QCDR,Process,Y,2.93 - 10.70,10.71 - 22.40,22.41 - 34.64,34.65 - 48.65,48.66 - 60.62,60.63 - 72.81,72.82 - 82.51,>= 82.52,No
Screening for Osteoporosis for Women Aged 65-85 Years of Age,039,Claims,Process,Y,23.81 - 37.69,37.7 - 44.99,45.0 - 51.64,51.65 - 56.97,56.98 - 63.40,63.41 - 70.68,70.69 - 79.99,>= 80.0,No
Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery,043,Registry/QCDR,Process,Y,97.62 - 98.81,98.82 - 99.99,--,--,--,--,--,100.00,Yes
Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery,044,Registry/QCDR,Process,Y,91.4 - 96.66,96.67 - 98.05,98.06 - 99.08,99.09 - 99.99,--,--,--,100.00,Yes
Medication Reconciliation Post-Discharge,046,Registry/QCDR,Process,Y,92.22 - 97.61,97.62 - 99.52,99.53 - 99.99,--,--,--,--,100.00,Yes
Medication Reconciliation Post-Discharge,046,Claims,Process,Y,96.0 - 99.99,--,--,--,--,--,--,100.00,Yes
Advance Care Plan,047,Registry/QCDR,Process,Y,4.09 - 23.35,23.36 - 49.23,49.24 - 68.20,68.21 - 82.83,82.84 - 91.53,91.54 - 96.69,96.7 - 99.39,>= 99.4,Yes
Advance Care Plan,047,Claims,Process,Y,18.18 - 51.73,51.74 - 86.64,86.65 - 95.42,95.43 - 98.73,98.74 - 99.66,99.67 - 99.99,--,100.00,Yes
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,048,Claims,Process,Y,1.3 - 3.27,3.28 - 7.46,7.47 - 83.23,83.24 - 98.41,98.42 - 99.99,--,--,100.00,Yes
Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older,048,Registry/QCDR,Process,Y,4.2 - 19.05,19.06 - 42.41,42.42 - 63.12,63.13 - 79.25,79.26 - 92.94,92.95 - 97.43,97.44 - 99.73,>= 99.74,Yes
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,050,Claims,Process,Y,64.52 - 95.23,95.24 - 98.97,98.98 - 99.99,--,--,--,--,100.00,Yes
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older,050,Registry/QCDR,Process,Y,25.58 - 46.14,46.15 - 59.08,59.09 - 70.96,70.97 - 79.16,79.17 - 87.67,87.68 - 94.02,94.03 - 99.16,>= 99.17,Yes
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,051,Claims,Process,Y,9.76 - 26.16,26.17 - 54.99,55.0 - 80.28,80.29 - 95.28,95.29 - 99.99,--,--,100.00,Yes
Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation,051,Registry/QCDR,Process,Y,17.16 - 34.17,34.18 - 50.67,50.68 - 66.25,66.26 - 76.86,76.87 - 85.19,85.2 - 93.86,93.87 - 98.73,>= 98.74,Yes
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,052,Claims,Process,Y,92.59 - 99.52,99.53 - 99.99,--,--,--,--,--,100.00,Yes
Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy,052,Registry/QCDR,Process,Y,62.5 - 73.32,73.33 - 83.92,83.93 - 90.05,90.06 - 97.49,97.5 - 99.99,--,--,100.00,Yes
Appropriate Treatment for Children with Upper Respiratory Infection (URI),065,EHR,Process,Y,75.95 - 84.73,84.74 - 88.63,88.64 - 91.52,91.53 - 93.40,93.41 - 94.98,94.99 - 96.38,96.39 - 97.92,>= 97.93,No
Appropriate Treatment for Children with Upper Respiratory Infection (URI),065,Registry/QCDR,Process,Y,89.05 - 93.39,93.4 - 95.89,95.9 - 97.73,97.74 - 98.71,98.72 - 99.45,99.46 - 99.99,--,100.00,No
Appropriate Testing for Children with Pharyngitis,066,EHR,Process,Y,17.35 - 45.21,45.22 - 59.88,59.89 - 68.92,68.93 - 77.04,77.05 - 81.25,81.26 - 85.24,85.25 - 89.55,>= 89.56,No
Appropriate Testing for Children with Pharyngitis,066,Registry/QCDR,Process,Y,56.0 - 65.87,65.88 - 72.84,72.85 - 77.77,77.78 - 81.97,81.98 - 85.70,85.71 - 89.28,89.29 - 92.71,>= 92.72,No
Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow,067,Registry/QCDR,Process,Y,8.33 - 17.64,17.65 - 24.31,24.32 - 31.81,31.82 - 47.49,47.5 - 69.99,70.0 - 98.59,98.6 - 99.99,100.00,No
Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry,070,Registry/QCDR,Process,Y,6.98 - 8.88,8.89 - 17.64,17.65 - 32.25,32.26 - 45.44,45.45 - 68.74,68.75 - 79.99,80.0 - 99.99,100.00,No
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,076,Registry/QCDR,Process,Y,89.59 - 96.54,96.55 - 98.74,98.75 - 99.88,99.89 - 99.99,--,--,--,100.00,Yes
Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections,076,Claims,Process,Y,91.84 - 98.77,98.78 - 99.99,--,--,--,--,--,100.00,Yes
Acute Otitis Externa (AOE): Topical Therapy,091,Claims,Process,Y,32.14 - 53.99,54.0 - 80.48,80.49 - 94.73,94.74 - 98.34,98.35 - 99.99,--,--,100.00,Yes
Acute Otitis Externa (AOE): Topical Therapy,091,Registry/QCDR,Process,Y,58.16 - 74.99,75.0 - 83.77,83.78 - 88.70,88.71 - 92.83,92.84 - 95.69,95.7 - 98.38,98.39 - 99.99,100.00,Yes
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,093,Claims,Process,Y,93.1 - 99.99,--,--,--,--,--,--,100.00,Yes
Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use,093,Registry/QCDR,Process,Y,73.91 - 83.73,83.74 - 89.99,90.0 - 93.42,93.43 - 95.82,95.83 - 97.72,97.73 - 99.65,99.66 - 99.99,100.00,Yes
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,099,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,099,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,100,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade,100,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients,102,Registry/QCDR,Process,Y,88.89 - 99.99,--,--,--,--,--,--,100.00,No
Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer,104,Registry/QCDR,Process,Y,54.29 - 82.34,82.35 - 95.65,95.66 - 97.38,97.39 - 98.47,98.48 - 99.99,--,--,100.00,No
Adult Major Depressive Disorder (MDD): Suicide Risk Assessment,107,EHR,Process,Y,0.75 - 2.59,2.6 - 7.99,8.0 - 17.13,17.14 - 30.30,30.31 - 43.77,43.78 - 59.00,59.01 - 82.75,>= 82.76,No
Osteoarthritis (OA): Function and Pain Assessment,109,Registry/QCDR,Process,Y,3.21 - 19.16,19.17 - 36.12,36.13 - 58.45,58.46 - 85.45,85.46 - 97.11,97.12 - 99.99,--,100.00,Yes
Osteoarthritis (OA): Function and Pain Assessment,109,Claims,Process,Y,76.8 - 96.42,96.43 - 98.66,98.67 - 99.76,99.77 - 99.99,--,--,--,100.00,Yes
Preventive Care and Screening: Influenza Immunization,110,EHR,Process,Y,3.35 - 12.67,12.68 - 21.28,21.29 - 29.12,29.13 - 36.49,36.5 - 44.62,44.63 - 53.17,53.18 - 64.98,>= 64.99,No
Preventive Care and Screening: Influenza Immunization,110,Claims,Process,Y,16.13 - 28.56,28.57 - 41.56,41.57 - 56.69,56.7 - 72.83,72.84 - 84.81,84.82 - 96.31,96.32 - 99.99,100.00,No
Preventive Care and Screening: Influenza Immunization,110,Registry/QCDR,Process,Y,11.37 - 26.23,26.24 - 39.27,39.28 - 51.26,51.27 - 61.64,61.65 - 71.12,71.13 - 81.97,81.98 - 92.93,>= 92.94,No
Pneumococcal Vaccination Status for Older Adults,111,Registry/QCDR,Process,Y,13.71 - 34.31,34.32 - 50.67,50.68 - 61.24,61.25 - 68.80,68.81 - 74.44,74.45 - 79.60,79.61 - 84.87,>= 84.88,No
Pneumococcal Vaccination Status for Older Adults,111,EHR,Process,Y,4.44 - 17.23,17.24 - 29.90,29.91 - 41.77,41.78 - 52.06,52.07 - 61.83,61.84 - 70.80,70.81 - 79.38,>= 79.39,No
Pneumococcal Vaccination Status for Older Adults,111,Claims,Process,Y,40.71 - 56.51,56.52 - 66.14,66.15 - 74.42,74.43 - 81.11,81.12 - 86.29,86.3 - 92.34,92.35 - 98.10,>= 98.11,No
Breast Cancer Screening,112,Claims,Process,Y,28.57 - 51.21,51.22 - 61.58,61.59 - 68.59,68.6 - 75.94,75.95 - 83.77,83.78 - 91.93,91.94 - 98.50,>= 98.51,No
Breast Cancer Screening,112,Registry/QCDR,Process,Y,7.44 - 19.78,19.79 - 34.28,34.29 - 47.48,47.49 - 55.70,55.71 - 64.19,64.2 - 73.39,73.4 - 82.16,>= 82.17,No
Breast Cancer Screening,112,EHR,Process,Y,7.32 - 20.77,20.78 - 33.32,33.33 - 43.17,43.18 - 51.55,51.56 - 58.97,58.98 - 65.80,65.81 - 72.86,>= 72.87,No
Colorectal Cancer Screening,113,EHR,Process,Y,2.6 - 12.98,12.99 - 25.25,25.26 - 35.54,35.55 - 45.64,45.65 - 55.53,55.54 - 65.13,65.14 - 74.47,>= 74.48,No
Colorectal Cancer Screening,113,Registry/QCDR,Process,Y,4.56 - 17.03,17.04 - 31.80,31.81 - 47.68,47.69 - 59.75,59.76 - 68.60,68.61 - 78.21,78.22 - 87.29,>= 87.3,No
Colorectal Cancer Screening,113,Claims,Process,Y,23.8 - 37.29,37.3 - 51.13,51.14 - 64.06,64.07 - 76.89,76.9 - 86.97,86.98 - 93.95,93.96 - 99.23,>= 99.24,No
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis,116,Registry/QCDR,Process,Y,37.5 - 48.34,48.35 - 60.73,60.74 - 71.29,71.3 - 81.49,81.5 - 91.66,91.67 - 97.82,97.83 - 99.61,>= 99.62,No
Diabetes: Eye Exam,117,EHR,Process,Y,6.84 - 16.66,16.67 - 25.92,25.93 - 36.04,36.05 - 49.99,50.0 - 75.25,75.26 - 95.30,95.31 - 98.54,>= 98.55,Yes
Diabetes: Eye Exam,117,Claims,Process,Y,25.78 - 79.34,79.35 - 96.50,96.51 - 99.99,--,--,--,--,100.00,Yes
Diabetes: Eye Exam,117,Registry/QCDR,Process,Y,23.19 - 64.05,64.06 - 89.06,89.07 - 95.49,95.5 - 97.84,97.85 - 99.37,99.38 - 99.99,--,100.00,Yes
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%),118,Registry/QCDR,Process,Y,71.43 - 77.04,77.05 - 79.64,79.65 - 81.93,81.94 - 84.11,84.12 - 85.70,85.71 - 88.45,88.46 - 91.42,>= 91.43,No
Diabetes: Medical Attention for Nephropathy,119,EHR,Process,Y,53.57 - 67.31,67.32 - 74.35,74.36 - 79.30,79.31 - 83.46,83.47 - 87.03,87.04 - 90.28,90.29 - 93.93,>= 93.94,No
Diabetes: Medical Attention for Nephropathy,119,Registry/QCDR,Process,Y,57.77 - 72.72,72.73 - 79.79,79.8 - 83.76,83.77 - 87.33,87.34 - 90.42,90.43 - 96.22,96.23 - 99.55,>= 99.56,No
Adult Kidney Disease: Blood Pressure Management,122,Registry/QCDR,IntermediateOutcome,Y,55.21 - 70.98,70.99 - 82.71,82.72 - 92.24,92.25 - 95.74,95.75 - 97.66,97.67 - 98.76,98.77 - 99.66,>= 99.67,No
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation",126,Registry/QCDR,Process,Y,26.73 - 54.45,54.46 - 74.20,74.21 - 84.71,84.72 - 91.69,91.7 - 97.21,97.22 - 99.74,99.75 - 99.99,100.00,Yes
"Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear",127,Registry/QCDR,Process,Y,22.52 - 49.06,49.07 - 69.51,69.52 - 81.47,81.48 - 89.92,89.93 - 97.07,97.08 - 99.64,99.65 - 99.99,100.00,Yes
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,EHR,Process,Y,17.49 - 22.05,22.06 - 25.98,25.99 - 30.67,30.68 - 37.39,37.4 - 48.72,48.73 - 65.39,65.4 - 81.93,>= 81.94,Yes
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Claims,Process,Y,32.59 - 49.64,49.65 - 78.22,78.23 - 93.89,93.9 - 99.08,99.09 - 99.99,--,--,100.00,Yes
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan,128,Registry/QCDR,Process,Y,22.92 - 33.85,33.86 - 52.40,52.41 - 70.21,70.22 - 83.85,83.86 - 92.29,92.3 - 97.02,97.03 - 99.26,>= 99.27,Yes
Documentation of Current Medications in the Medical Record,130,EHR,Process,Y,66.02 - 84.84,84.85 - 91.68,91.69 - 95.18,95.19 - 97.35,97.36 - 98.70,98.71 - 99.46,99.47 - 99.84,>= 99.85,Yes
Documentation of Current Medications in the Medical Record,130,Registry/QCDR,Process,Y,43.64 - 88.88,88.89 - 97.18,97.19 - 99.08,99.09 - 99.68,99.69 - 99.91,99.92 - 99.99,--,100.00,Yes
Documentation of Current Medications in the Medical Record,130,Claims,Process,Y,93.39 - 98.64,98.65 - 99.68,99.69 - 99.99,--,--,--,--,100.00,Yes
Pain Assessment and Follow-Up,131,Claims,Process,Y,68.35 - 96.57,96.58 - 99.56,99.57 - 99.99,--,--,--,--,100.00,Yes
Pain Assessment and Follow-Up,131,Registry/QCDR,Process,Y,1.25 - 15.66,15.67 - 39.09,39.1 - 67.03,67.04 - 85.45,85.46 - 94.57,94.58 - 98.87,98.88 - 99.99,100.00,Yes
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Claims,Process,Y,0.89 - 20.71,20.72 - 64.84,64.85 - 90.21,90.22 - 99.54,99.55 - 99.99,--,--,100.00,Yes
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,Registry/QCDR,Process,Y,2.82 - 16.96,16.97 - 38.30,38.31 - 61.24,61.25 - 74.39,74.4 - 84.98,84.99 - 93.13,93.14 - 98.38,>= 98.39,Yes
Preventive Care and Screening: Screening for Depression and Follow-Up Plan,134,EHR,Process,Y,1.83 - 5.65,5.66 - 10.73,10.74 - 16.72,16.73 - 26.74,26.75 - 40.47,40.48 - 56.30,56.31 - 73.24,>= 73.25,Yes
Melanoma: Continuity of Care - Recall System,137,Registry/QCDR,Structure,Y,67.24 - 91.01,91.02 - 97.65,97.66 - 99.99,--,--,--,--,100.00,No
Melanoma: Coordination of Care,138,Registry/QCDR,Process,Y,25.49 - 56.89,56.9 - 82.75,82.76 - 95.09,95.1 - 99.99,--,--,--,100.00,No
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement,140,Registry/QCDR,Process,Y,20.3 - 41.71,41.72 - 55.64,55.65 - 66.57,66.58 - 75.38,75.39 - 82.50,82.51 - 88.37,88.38 - 93.71,>= 93.72,Yes
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement,140,Claims,Process,Y,93.27 - 99.59,99.6 - 99.99,--,--,--,--,--,100.00,Yes
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Registry/QCDR,Outcome,Y,9.16 - 15.56,15.57 - 19.01,19.02 - 22.45,22.46 - 26.66,26.67 - 36.86,36.87 - 67.73,67.74 - 90.69,>= 90.7,Yes
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care,141,Claims,Outcome,Y,96.61 - 99.99,--,--,--,--,--,--,100.00,Yes
Oncology: Medical and Radiation - Pain Intensity Quantified,143,Registry/QCDR,Process,Y,67.46 - 85.87,85.88 - 94.99,95.0 - 97.76,97.77 - 99.52,99.53 - 99.99,--,--,100.00,Yes
Oncology: Medical and Radiation - Pain Intensity Quantified,143,EHR,Process,Y,46.53 - 77.36,77.37 - 89.09,89.1 - 93.40,93.41 - 95.94,95.95 - 97.42,97.43 - 98.55,98.56 - 99.54,>= 99.55,Yes
Oncology: Medical and Radiation - Plan of Care for Moderate to Severe Pain,144,Registry/QCDR,Process,Y,30.12 - 64.39,64.4 - 82.51,82.52 - 90.93,90.94 - 96.29,96.3 - 98.75,98.76 - 99.99,--,100.00,Yes
Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy,145,Claims,Process,Y,58.62 - 86.10,86.11 - 94.43,94.44 - 97.21,97.22 - 98.60,98.61 - 99.99,--,--,100.00,Yes
Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy,145,Registry/QCDR,Process,Y,47.45 - 79.30,79.31 - 90.76,90.77 - 96.25,96.26 - 98.56,98.57 - 99.69,99.7 - 99.99,--,100.00,Yes
Radiology: Inappropriate Use of 'Probably Benign' Assessment Category in Screening Mammograms,146,Registry/QCDR,Process,Y,0.66 - 0.26,0.25 - 0.13,0.12 - 0.06,0.05 - 0.02,0.01 - 0.01,--,--,0.00,Yes
Radiology: Inappropriate Use of 'Probably Benign' Assessment Category in Screening Mammograms,146,Claims,Process,Y,0.51 - 0.20,0.19 - 0.01,--,--,--,--,--,0.00,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Claims,Process,Y,61.9 - 86.95,86.96 - 95.44,95.45 - 98.14,98.15 - 99.99,--,--,--,100.00,Yes
Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy,147,Registry/QCDR,Process,Y,76.92 - 91.10,91.11 - 97.37,97.38 - 99.77,99.78 - 99.99,--,--,--,100.00,Yes
Falls: Risk Assessment,154,Registry/QCDR,Process,Y,30.88 - 67.16,67.17 - 84.63,84.64 - 94.43,94.44 - 98.51,98.52 - 99.99,--,--,100.00,Yes
Falls: Risk Assessment,154,Claims,Process,Y,89.13 - 98.35,98.36 - 99.99,--,--,--,--,--,100.00,Yes
Falls: Plan of Care,155,Claims,Process,Y,28.57 - 97.29,97.3 - 99.99,--,--,--,--,--,100.00,Yes
Falls: Plan of Care,155,Registry/QCDR,Process,Y,26.42 - 57.91,57.92 - 76.35,76.36 - 86.20,86.21 - 94.79,94.8 - 98.05,98.06 - 99.99,--,100.00,Yes
Oncology: Radiation Dose Limits to Normal Tissues,156,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Diabetes: Foot Exam,163,EHR,Process,Y,2.99 - 9.08,9.09 - 18.11,18.12 - 27.99,28.0 - 40.55,40.56 - 54.26,54.27 - 68.38,68.39 - 82.16,>= 82.17,No
Coronary Artery Bypass Graft (CABG): Prolonged Intubation,164,Registry/QCDR,Outcome,Y,13.64 - 11.55,11.54 - 8.71,8.7 - 6.83,6.82 - 5.85,5.84 - 4.68,4.67 - 3.98,3.97 - 2.87,<= 2.86,No
Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate,165,Registry/QCDR,Outcome,Y,1.03 - 0.01,--,--,--,--,--,--,0.00,Yes
Coronary Artery Bypass Graft (CABG): Stroke,166,Registry/QCDR,Outcome,Y,3.23 - 2.39,2.38 - 1.97,1.96 - 1.46,1.45 - 1.18,1.17 - 0.01,--,--,0.00,Yes
Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure,167,Registry/QCDR,Outcome,Y,3.85 - 2.97,2.96 - 2.28,2.27 - 1.83,1.82 - 1.34,1.33 - 0.91,0.9 - 0.01,--,0.00,Yes
Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration,168,Registry/QCDR,Outcome,Y,6.06 - 4.09,4.08 - 3.27,3.26 - 2.32,2.31 - 1.80,1.79 - 1.24,1.23 - 0.88,0.87 - 0.01,0.00,Yes
Rheumatoid Arthritis (RA): Tuberculosis Screening,176,Registry/QCDR,Process,Y,27.78 - 42.07,42.08 - 59.08,59.09 - 74.45,74.46 - 89.15,89.16 - 95.73,95.74 - 99.99,--,100.00,No
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity,177,Registry/QCDR,Process,Y,40.91 - 67.04,67.05 - 78.72,78.73 - 87.95,87.96 - 93.12,93.13 - 96.75,96.76 - 99.60,99.61 - 99.99,100.00,Yes
Rheumatoid Arthritis (RA): Functional Status Assessment,178,Registry/QCDR,Process,Y,45.46 - 76.58,76.59 - 86.03,86.04 - 91.40,91.41 - 95.57,95.58 - 98.75,98.76 - 99.83,99.84 - 99.99,100.00,Yes
Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis,179,Registry/QCDR,Process,Y,31.81 - 56.72,56.73 - 73.66,73.67 - 81.85,81.86 - 89.77,89.78 - 96.88,96.89 - 99.99,--,100.00,Yes
Rheumatoid Arthritis (RA): Glucocorticoid Management,180,Registry/QCDR,Process,Y,40.91 - 61.47,61.48 - 73.22,73.23 - 80.82,80.83 - 87.21,87.22 - 91.78,91.79 - 96.69,96.7 - 99.99,100.00,Yes
Elder Maltreatment Screen and Follow-Up Plan,181,Registry/QCDR,Process,Y,25.71 - 62.55,62.56 - 71.37,71.38 - 81.38,81.39 - 92.05,92.06 - 98.18,98.19 - 99.81,99.82 - 99.99,100.00,Yes
Elder Maltreatment Screen and Follow-Up Plan,181,Claims,Process,Y,12.11 - 98.23,98.24 - 99.99,--,--,--,--,--,100.00,Yes
Functional Outcome Assessment,182,Claims,Process,Y,88.24 - 99.63,99.64 - 99.99,--,--,--,--,--,100.00,Yes
Functional Outcome Assessment,182,Registry/QCDR,Process,Y,1.39 - 4.78,4.79 - 7.34,7.35 - 16.15,16.16 - 87.12,87.13 - 98.87,98.88 - 99.24,99.25 - 99.90,>= 99.91,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps
- Avoidance of Inappropriate Use",185,Claims,Process,Y,96.92 - 98.79,98.8 - 99.99,--,--,--,--,--,100.00,Yes
"Colonoscopy Interval for Patients with a History of Adenomatous Polyps
- Avoidance of Inappropriate Use",185,Registry/QCDR,Process,Y,27.27 - 58.32,58.33 - 78.94,78.95 - 94.62,94.63 - 98.04,98.05 - 99.51,99.52 - 99.99,--,100.00,Yes
Stroke and Stroke Rehabilitation: Thrombolytic Therapy,187,Registry/QCDR,Process,Y,52.94 - 72.21,72.22 - 80.89,80.9 - 92.85,92.86 - 97.29,97.3 - 99.99,--,--,100.00,Yes
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,EHR,Outcome,Y,66.87 - 82.82,82.83 - 90.41,90.42 - 94.11,94.12 - 96.14,96.15 - 97.44,97.45 - 98.44,98.45 - 99.26,>= 99.27,No
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery,191,Registry/QCDR,Outcome,Y,87.5 - 93.64,93.65 - 96.50,96.51 - 97.77,97.78 - 98.91,98.92 - 99.99,--,--,100.00,No
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,EHR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures,192,Registry/QCDR,Outcome,Y,1.21 - 0.29,0.28 - 0.01,--,--,--,--,--,0.00,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Registry/QCDR,Process,Y,93.52 - 98.13,98.14 - 99.48,99.49 - 99.97,99.98 - 99.99,--,--,--,100.00,Yes
Radiology: Stenosis Measurement in Carotid Imaging Reports,195,Claims,Process,Y,90.56 - 97.25,97.26 - 99.21,99.22 - 99.99,--,--,--,--,100.00,Yes
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,EHR,Process,Y,51.85 - 65.10,65.11 - 70.97,70.98 - 75.60,75.61 - 79.16,79.17 - 82.17,82.18 - 84.99,85.0 - 88.00,>= 88.01,No
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,Registry/QCDR,Process,Y,54.31 - 72.48,72.49 - 81.21,81.22 - 85.68,85.69 - 88.60,88.61 - 91.07,91.08 - 93.15,93.16 - 95.35,>= 95.36,No
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet,204,Claims,Process,Y,83.19 - 87.35,87.36 - 89.99,90.0 - 92.26,92.27 - 94.22,94.23 - 96.45,96.46 - 98.99,99.0 - 99.99,100.00,No
Melanoma: Overutilization of Imaging Studies in Melanoma,224,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Radiology: Reminder System for Screening Mammograms,225,Claims,Structure,Y,99.15 - 99.99,--,--,--,--,--,--,100.00,Yes
Radiology: Reminder System for Screening Mammograms,225,Registry/QCDR,Structure,Y,--,--,--,--,--,--,--,100.00,Yes
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Registry/QCDR,Process,Y,10.45 - 19.71,19.72 - 32.07,32.08 - 46.90,46.91 - 65.69,65.7 - 82.97,82.98 - 94.22,94.23 - 99.99,100.00,No
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,Claims,Process,Y,95.86 - 98.55,98.56 - 99.71,99.72 - 99.99,--,--,--,--,100.00,No
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention,226,EHR,Process,Y,7.27 - 17.35,17.36 - 33.32,33.33 - 55.82,55.83 - 73.97,73.98 - 82.95,82.96 - 88.08,88.09 - 92.46,>= 92.47,No
Controlling High Blood Pressure,236,EHR,IntermediateOutcome,Y,43.06 - 51.67,51.68 - 57.08,57.09 - 61.54,61.55 - 65.42,65.43 - 69.08,69.09 - 72.87,72.88 - 77.28,>= 77.29,No
Controlling High Blood Pressure,236,Registry/QCDR,IntermediateOutcome,Y,41.75 - 52.29,52.3 - 58.50,58.51 - 64.09,64.1 - 68.69,68.7 - 73.08,73.09 - 78.19,78.2 - 84.36,>= 84.37,No
Controlling High Blood Pressure,236,Claims,IntermediateOutcome,Y,50.52 - 59.27,59.28 - 65.18,65.19 - 69.77,69.78 - 74.30,74.31 - 78.58,78.59 - 83.60,83.61 - 89.01,>= 89.02,No
Use of High-Risk Medications in the Elderly,238,EHR,Process,Y,11.49 - 6.11,6.1 - 3.10,3.09 - 1.38,1.37 - 0.58,0.57 - 0.22,0.21 - 0.01,--,0.00,Yes
Use of High-Risk Medications in the Elderly,238,Registry/QCDR,Process,Y,8.52 - 3.29,3.28 - 1.45,1.44 - 0.67,0.66 - 0.34,0.33 - 0.17,0.16 - 0.01,--,0.00,Yes
Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents,239,EHR,Process,Y,21.79 - 27.67,27.68 - 30.55,30.56 - 32.11,32.12 - 33.32,33.33 - 34.71,34.72 - 39.96,39.97 - 51.28,>= 51.29,No
Childhood Immunization Status,240,EHR,Process,Y,5.26 - 11.53,11.54 - 18.89,18.9 - 24.85,24.86 - 29.42,29.43 - 34.25,34.26 - 38.51,38.52 - 43.58,>= 43.59,No
Cardiac Rehabilitation Patient Referral from an Outpatient Setting,243,Registry/QCDR,Process,Y,2.6 - 5.64,5.65 - 8.88,8.89 - 14.36,14.37 - 20.74,20.75 - 28.83,28.84 - 38.93,38.94 - 52.89,>= 52.9,No
Barrett's Esophagus,249,Registry/QCDR,Process,Y,99.81 - 99.99,--,--,--,--,--,--,100.00,Yes
Barrett's Esophagus,249,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Radical Prostatectomy Pathology Reporting,250,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Radical Prostatectomy Pathology Reporting,250,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients,251,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients,251,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain,254,Registry/QCDR,Process,Y,80.37 - 88.70,88.71 - 92.21,92.22 - 94.82,94.83 - 96.29,96.3 - 97.86,97.87 - 98.99,99.0 - 99.99,100.00,No
"Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)",260,Registry/QCDR,Outcome,Y,85.0 - 85.70,85.71 - 88.23,88.24 - 88.50,88.51 - 91.94,91.95 - 95.23,95.24 - 95.99,96.0 - 97.86,>= 97.87,No
Image Confirmation of Successful Excision of Image-Localized Breast Lesion,262,Registry/QCDR,Process,Y,99.17 - 99.99,--,--,--,--,--,--,100.00,Yes
Preoperative Diagnosis of Breast Cancer,263,Registry/QCDR,Process,Y,97.5 - 98.25,98.26 - 99.03,99.04 - 99.99,--,--,--,--,100.00,Yes
Sentinel Lymph Node Biopsy for Invasive Breast Cancer,264,Registry/QCDR,Process,Y,95.0 - 97.72,97.73 - 98.84,98.85 - 99.43,99.44 - 99.99,--,--,--,100.00,Yes
Biopsy Follow-Up,265,Registry/QCDR,Process,Y,25.09 - 72.27,72.28 - 89.67,89.68 - 97.50,97.51 - 99.78,99.79 - 99.99,--,--,100.00,Yes
Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy,268,Registry/QCDR,Process,Y,8.33 - 26.46,26.47 - 33.32,33.33 - 38.29,38.3 - 64.70,64.71 - 81.81,81.82 - 89.99,90.0 - 99.99,100.00,No
Sleep Apnea: Assessment of Sleep Symptoms,276,Registry/QCDR,Process,Y,4.98 - 17.77,17.78 - 47.18,47.19 - 64.70,64.71 - 79.01,79.02 - 87.53,87.54 - 95.69,95.7 - 99.99,100.00,No
Sleep Apnea: Severity Assessment at Initial Diagnosis,277,Registry/QCDR,Process,Y,5.68 - 23.93,23.94 - 54.32,54.33 - 80.46,80.47 - 90.62,90.63 - 99.23,99.24 - 99.99,--,100.00,Yes
Sleep Apnea: Positive Airway Pressure Therapy Prescribed,278,Registry/QCDR,Process,Y,91.0 - 96.47,96.48 - 97.20,97.21 - 98.24,98.25 - 99.33,99.34 - 99.99,--,--,100.00,No
Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy,279,Registry/QCDR,Process,Y,49.0 - 73.80,73.81 - 88.55,88.56 - 94.00,94.01 - 98.66,98.67 - 99.99,--,--,100.00,Yes
Dementia: Cognitive Assessment,281,EHR,Process,Y,3.57 - 7.68,7.69 - 13.99,14.0 - 25.77,25.78 - 43.86,43.87 - 67.34,67.35 - 80.71,80.72 - 92.30,>= 92.31,No
Dementia: Functional Status Assessment,282,Registry/QCDR,Process,Y,28.17 - 57.92,57.93 - 77.88,77.89 - 89.85,89.86 - 96.66,96.67 - 98.67,98.68 - 99.99,--,100.00,Yes
Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management,283,Registry/QCDR,Process,Y,51.36 - 83.82,83.83 - 94.08,94.09 - 98.04,98.05 - 99.77,99.78 - 99.99,--,--,100.00,Yes
Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia,286,Registry/QCDR,Process,Y,19.57 - 39.07,39.08 - 78.29,78.3 - 90.90,90.91 - 98.29,98.3 - 99.99,--,--,100.00,Yes
Dementia: Education and Support of Caregivers for Patients with Dementia,288,Registry/QCDR,Process,Y,13.68 - 38.62,38.63 - 55.99,56.0 - 76.46,76.47 - 86.83,86.84 - 99.99,--,--,100.00,Yes
Parkinson's Disease: Psychiatric Symptoms Assessment for Patients with Parkinson's Disease,290,Registry/QCDR,Process,Y,8.82 - 16.12,16.13 - 29.99,30.0 - 40.97,40.98 - 51.84,51.85 - 79.30,79.31 - 99.99,--,100.00,Yes
Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson's Disease,291,Registry/QCDR,Process,Y,10.0 - 33.05,33.06 - 63.46,63.47 - 89.89,89.9 - 99.99,--,--,--,100.00,Yes
Parkinson's Disease: Rehabilitative Therapy Options,293,Registry/QCDR,Process,Y,23.12 - 37.17,37.18 - 69.99,70.0 - 83.86,83.87 - 95.65,95.66 - 99.99,--,--,100.00,Yes
Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery,303,Registry/QCDR,PatientReportedOutcome,Y,26.09 - 36.80,36.81 - 48.69,48.7 - 56.66,56.67 - 69.96,69.97 - 82.72,82.73 - 94.22,94.23 - 98.56,>= 98.57,No
Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery,304,Registry/QCDR,PatientReportedOutcome,Y,16.36 - 27.82,27.83 - 56.16,56.17 - 66.31,66.32 - 75.75,75.76 - 86.38,86.39 - 94.93,94.94 - 98.67,>= 98.68,No
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment,305,EHR,Process,Y,0.37 - 0.49,0.5 - 0.80,0.81 - 1.14,1.15 - 1.43,1.44 - 1.91,1.92 - 2.74,2.75 - 4.55,>= 4.56,No
Cervical Cancer Screening,309,EHR,Process,Y,3.41 - 10.63,10.64 - 17.59,17.6 - 24.55,24.56 - 32.09,32.1 - 40.73,40.74 - 49.12,49.13 - 59.16,>= 59.17,No
Chlamydia Screening for Women,310,EHR,Process,Y,6.9 - 15.21,15.22 - 22.04,22.05 - 28.41,28.42 - 35.12,35.13 - 40.15,40.16 - 46.80,46.81 - 55.80,>= 55.81,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Claims,Process,Y,29.32 - 46.78,46.79 - 67.22,67.23 - 86.80,86.81 - 95.58,95.59 - 98.96,98.97 - 99.99,--,100.00,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,EHR,Process,Y,12.25 - 19.60,19.61 - 23.89,23.9 - 27.74,27.75 - 31.40,31.41 - 35.28,35.29 - 40.15,40.16 - 47.40,>= 47.41,No
Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented,317,Registry/QCDR,Process,Y,16.37 - 28.66,28.67 - 37.73,37.74 - 45.33,45.34 - 53.74,53.75 - 65.09,65.1 - 84.29,84.3 - 96.68,>= 96.69,No
Falls: Screening for Future Fall Risk,318,EHR,Process,Y,1.39 - 13.12,13.13 - 30.92,30.93 - 49.07,49.08 - 65.27,65.28 - 77.34,77.35 - 86.61,86.62 - 93.56,>= 93.57,No
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Registry/QCDR,Process,Y,59.09 - 82.75,82.76 - 89.28,89.29 - 92.58,92.59 - 95.10,95.11 - 97.35,97.36 - 98.51,98.52 - 99.99,100.00,Yes
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients,320,Claims,Process,Y,85.94 - 93.09,93.1 - 97.15,97.16 - 99.99,--,--,--,--,100.00,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients,322,Registry/QCDR,Efficiency,Y,1.09 - 0.13,0.12 - 0.01,--,--,--,--,--,0.00,Yes
Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI),323,Registry/QCDR,Efficiency,Y,1.09 - 0.01,--,--,--,--,--,--,0.00,Yes
"Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients",324,Registry/QCDR,Efficiency,Y,21.33 - 8.38,8.37 - 2.18,2.17 - 0.14,0.13 - 0.01,--,--,--,0.00,Yes
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Registry/QCDR,Process,Y,68.06 - 76.44,76.45 - 82.91,82.92 - 87.21,87.22 - 95.03,95.04 - 98.03,98.04 - 99.99,--,100.00,Yes
Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy,326,Claims,Process,Y,93.14 - 98.45,98.46 - 99.99,--,--,--,--,--,100.00,Yes
Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse),331,Registry/QCDR,Process,Y,87.18 - 76.10,76.09 - 65.68,65.67 - 54.30,54.29 - 43.60,43.59 - 34.33,34.32 - 23.18,23.17 - 13.05,<= 13.04,No
Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use),332,Registry/QCDR,Process,Y,58.01 - 79.40,79.41 - 92.30,92.31 - 96.14,96.15 - 98.08,98.09 - 98.96,98.97 - 99.87,99.88 - 99.99,100.00,Yes
Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse),333,Registry/QCDR,Efficiency,Y,6.37 - 2.71,2.7 - 1.17,1.16 - 0.21,0.2 - 0.01,--,--,--,0.00,Yes
Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse),334,Registry/QCDR,Efficiency,Y,3.3 - 0.91,0.9 - 0.01,--,--,--,--,--,0.00,Yes
"Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier",337,Registry/QCDR,Process,Y,27.59 - 52.34,52.35 - 71.07,71.08 - 82.17,82.18 - 90.47,90.48 - 95.23,95.24 - 98.57,98.58 - 99.99,100.00,No
HIV Viral Load Suppression,338,Registry/QCDR,Outcome,Y,49.37 - 59.08,59.09 - 81.81,81.82 - 83.96,83.97 - 86.59,86.6 - 92.68,92.69 - 95.76,95.77 - 99.28,>= 99.29,No
HIV Medical Visit Frequency,340,Registry/QCDR,Process,Y,40.26 - 48.39,48.4 - 56.02,56.03 - 62.43,62.44 - 70.20,70.21 - 76.91,76.92 - 90.37,90.38 - 95.34,>= 95.35,No
Pain Brought Under Control Within 48 Hours,342,Registry/QCDR,Outcome,Y,83.99 - 99.50,99.51 - 99.99,--,--,--,--,--,100.00,Yes
Screening Colonoscopy Adenoma Detection Rate,343,Registry/QCDR,Outcome,Y,17.95 - 28.59,28.6 - 33.63,33.64 - 37.49,37.5 - 41.73,41.74 - 45.29,45.3 - 49.41,49.42 - 60.12,>= 60.13,No
Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy,350,Registry/QCDR,Process,Y,88.87 - 98.02,98.03 - 99.99,--,--,--,--,--,100.00,Yes
Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation,351,Registry/QCDR,Process,Y,92.23 - 98.80,98.81 - 99.99,--,--,--,--,--,100.00,Yes
Total Knee Replacement: Preoperative Antibiotic Infusion with Proximal Tourniquet,352,Registry/QCDR,Process,Y,96.76 - 99.99,--,--,--,--,--,--,100.00,Yes
Total Knee Replacement: Identification of Implanted Prosthesis in Operative Report,353,Registry/QCDR,Process,Y,97.14 - 99.99,--,--,--,--,--,--,100.00,Yes
Anastomotic Leak Intervention,354,Registry/QCDR,Outcome,Y,8.7 - 5.01,5.0 - 1.71,1.7 - 0.51,0.5 - 0.01,--,--,--,0.00,Yes
Unplanned Reoperation within the 30 Day Postoperative Period,355,Registry/QCDR,Outcome,Y,4.69 - 2.59,2.58 - 1.68,1.67 - 0.96,0.95 - 0.37,0.36 - 0.01,--,--,0.00,Yes
Unplanned Hospital Readmission within 30 Days of Principal Procedure,356,Registry/QCDR,Outcome,Y,6.19 - 3.71,3.7 - 2.63,2.62 - 1.60,1.59 - 0.89,0.88 - 0.01,--,--,0.00,Yes
Surgical Site Infection (SSI),357,Registry/QCDR,Outcome,Y,5.58 - 2.26,2.25 - 1.36,1.35 - 0.69,0.68 - 0.01,--,--,--,0.00,Yes
Patient-Centered Surgical Risk Assessment and Communication,358,Registry/QCDR,Process,Y,4.81 - 35.06,35.07 - 66.84,66.85 - 87.59,87.6 - 97.36,97.37 - 99.99,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Utilization of a Standardized Nomenclature for Computed Tomography (CT) Imaging Description,359,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies,360,Registry/QCDR,Process,Y,2.45 - 5.19,5.2 - 37.89,37.9 - 93.76,93.77 - 98.90,98.91 - 99.99,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Reporting to a Radiation Dose Index Registry,361,Registry/QCDR,Structure,Y,98.77 - 99.99,--,--,--,--,--,--,100.00,Yes
Optimizing Patient Exposure to Ionizing Radiation: Computed Tomography (CT) Images Available for Patient Follow-up and Comparison Purposes,362,Registry/QCDR,Structure,Y,97.32 - 99.99,--,--,--,--,--,--,100.00,Yes
"Optimizing Patient Exposure to Ionizing Radiation: Search for Prior Computed Tomography (CT) Studies Through a Secure, Authorized, Media-Free, Shared Archive",363,Registry/QCDR,Structure,Y,93.53 - 99.32,99.33 - 99.99,--,--,--,--,--,100.00,No
Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines,364,Registry/QCDR,Process,Y,52.4 - 68.08,68.09 - 78.40,78.41 - 85.70,85.71 - 91.79,91.8 - 98.07,98.08 - 99.99,--,100.00,Yes
Follow-Up Care for Children Prescribed ADHD Medication (ADD),366,EHR,Process,Y,10.0 - 13.45,13.46 - 16.66,16.67 - 23.26,23.27 - 26.41,26.42 - 29.65,29.66 - 31.66,31.67 - 38.39,>= 38.4,No
Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use,367,EHR,Process,Y,0.32 - 0.73,0.74 - 2.00,2.01 - 2.81,2.82 - 3.61,3.62 - 4.95,4.96 - 13.09,13.1 - 26.91,>= 26.92,No
Pregnant women that had HBsAg testing,369,EHR,Process,Y,41.0 - 63.75,63.76 - 75.75,75.76 - 83.77,83.78 - 87.99,88.0 - 90.83,90.84 - 93.91,93.92 - 95.74,>= 95.75,No
Depression Remission at Twelve Months,370,EHR,Outcome,Y,1.42 - 2.32,2.33 - 3.20,3.21 - 4.61,4.62 - 6.99,7.0 - 9.59,9.6 - 14.28,14.29 - 20.25,>= 20.26,No
Depression Utilization of the PHQ-9 Tool,371,EHR,Process,Y,2.48 - 4.45,4.46 - 7.25,7.26 - 10.43,10.44 - 14.42,14.43 - 19.57,19.58 - 25.70,25.71 - 35.40,>= 35.41,No
Maternal Depression Screening,372,EHR,Process,Y,3.54 - 4.99,5.0 - 16.99,17.0 - 22.99,23.0 - 30.69,30.7 - 35.70,35.71 - 42.58,42.59 - 58.37,>= 58.38,No
Hypertension: Improvement in Blood Pressure,373,EHR,IntermediateOutcome,Y,12.16 - 18.51,18.52 - 24.02,24.03 - 29.02,29.03 - 33.16,33.17 - 36.98,36.99 - 40.73,40.74 - 44.73,>= 44.74,No
Closing the Referral Loop: Receipt of Specialist Report,374,Registry/QCDR,Process,Y,5.66 - 36.59,36.6 - 68.63,68.64 - 87.19,87.2 - 96.20,96.21 - 99.99,--,--,100.00,No
Closing the Referral Loop: Receipt of Specialist Report,374,EHR,Process,Y,2.63 - 6.99,7.0 - 14.80,14.81 - 25.94,25.95 - 37.69,37.7 - 49.99,50.0 - 62.15,62.16 - 75.22,>= 75.23,No
Functional Status Assessment for Total Knee Replacement,375,EHR,Process,Y,1.43 - 2.32,2.33 - 4.34,4.35 - 7.18,7.19 - 14.99,15.0 - 26.66,26.67 - 37.03,37.04 - 55.55,>= 55.56,No
Functional Status Assessment for Total Hip Replacement,376,EHR,Process,Y,1.56 - 3.28,3.29 - 4.99,5.0 - 10.74,10.75 - 17.77,17.78 - 23.28,23.29 - 35.19,35.2 - 48.13,>= 48.14,No
Functional Status Assessments for Congestive Heart Failure,377,EHR,Process,Y,0.63 - 1.21,1.22 - 1.99,2.0 - 2.99,3.0 - 4.11,4.12 - 5.27,5.28 - 5.86,5.87 - 9.79,>= 9.8,No
Children Who Have Dental Decay or Cavities,378,EHR,Outcome,Y,1.37 - 0.59,0.58 - 0.14,0.13 - 0.01,--,--,--,--,0.00,Yes
"Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists",379,EHR,Process,Y,0.06 - 0.20,0.21 - 0.50,0.51 - 1.07,1.08 - 2.40,2.41 - 3.55,3.56 - 4.75,4.76 - 7.03,>= 7.04,No
Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment,382,EHR,Process,Y,1.49 - 5.35,5.36 - 12.83,12.84 - 20.36,20.37 - 27.96,27.97 - 35.99,36.0 - 46.14,46.15 - 65.87,>= 65.88,No
Adherence to Antipsychotic Medications For Individuals with Schizophrenia,383,Registry/QCDR,IntermediateOutcome,Y,39.13 - 73.20,73.21 - 81.74,81.75 - 89.99,90.0 - 98.84,98.85 - 99.99,--,--,100.00,No
Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery,384,Registry/QCDR,Outcome,Y,91.43 - 97.70,97.71 - 99.99,--,--,--,--,--,100.00,No
Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery,385,Registry/QCDR,Outcome,Y,9.09 - 13.08,13.09 - 16.32,16.33 - 19.22,19.23 - 21.75,21.76 - 24.72,24.73 - 30.24,30.25 - 34.77,>= 34.78,No
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy),388,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,Yes
Cataract Surgery: Difference Between Planned and Final Refraction,389,Registry/QCDR,Outcome,Y,0.45 - 0.69,0.7 - 0.94,0.95 - 1.16,1.17 - 1.48,1.49 - 1.89,1.9 - 2.55,2.56 - 17.08,>= 17.09,No
Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options,390,Registry/QCDR,Process,Y,36.62 - 53.58,53.59 - 76.23,76.24 - 89.16,89.17 - 99.99,--,--,--,100.00,Yes
Immunizations for Adolescents,394,Registry/QCDR,Process,Y,1.75 - 2.43,2.44 - 4.75,4.76 - 6.66,6.67 - 13.78,13.79 - 14.99,15.0 - 16.66,16.67 - 27.58,>= 27.59,No
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Registry/QCDR,Process,Y,99.62 - 99.99,--,--,--,--,--,--,100.00,Yes
Lung Cancer Reporting (Biopsy/Cytology Specimens),395,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Lung Cancer Reporting (Resection Specimens),396,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Melanoma Reporting,397,Registry/QCDR,Process,Y,90.68 - 99.99,--,--,--,--,--,--,100.00,Yes
Melanoma Reporting,397,Claims,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Optimal Asthma Control,398,Registry/QCDR,Outcome,Y,15.5 - 41.11,41.12 - 54.16,54.17 - 73.48,73.49 - 84.57,84.58 - 96.71,96.72 - 99.99,--,100.00,No
One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk,400,Registry/QCDR,Process,Y,0.39 - 0.94,0.95 - 1.66,1.67 - 2.40,2.41 - 3.90,3.91 - 10.57,10.58 - 39.35,39.36 - 54.94,>= 54.95,No
Tobacco Use and Help with Quitting Among Adolescents,402,Registry/QCDR,Process,Y,77.35 - 87.62,87.63 - 92.49,92.5 - 95.23,95.24 - 97.05,97.06 - 98.40,98.41 - 99.39,99.4 - 99.99,100.00,Yes
Anesthesiology Smoking Abstinence,404,Registry/QCDR,IntermediateOutcome,Y,36.24 - 46.52,46.53 - 56.38,56.39 - 62.91,62.92 - 69.55,69.56 - 74.99,75.0 - 79.32,79.33 - 90.09,>= 90.1,No
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Registry/QCDR,Process,Y,10.66 - 2.71,2.7 - 0.16,0.15 - 0.01,--,--,--,--,0.00,Yes
Appropriate Follow-up Imaging for Incidental Abdominal Lesions,405,Claims,Process,Y,19.59 - 4.56,4.55 - 0.01,--,--,--,--,--,0.00,Yes
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Registry/QCDR,Process,Y,17.39 - 7.33,7.32 - 3.40,3.39 - 0.75,0.74 - 0.01,--,--,--,0.00,No
Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients,406,Claims,Process,Y,5.32 - 2.02,2.01 - 0.01,--,--,--,--,--,0.00,No
Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia,407,Registry/QCDR,Process,Y,80.95 - 96.05,96.06 - 98.40,98.41 - 99.99,--,--,--,--,100.00,Yes
Opioid Therapy Follow-up Evaluation,408,Registry/QCDR,Process,Y,28.4 - 68.34,68.35 - 81.50,81.51 - 94.23,94.24 - 98.90,98.91 - 99.99,--,--,100.00,Yes
Psoriasis: Clinical Response to Systemic Medications,410,Registry/QCDR,Outcome,Y,14.85 - 34.77,34.78 - 51.27,51.28 - 64.28,64.29 - 76.72,76.73 - 85.36,85.37 - 93.74,93.75 - 99.99,100.00,No
Documentation of Signed Opioid Treatment Agreement,412,Registry/QCDR,Process,Y,40.91 - 70.97,70.98 - 83.99,84.0 - 96.91,96.92 - 99.99,--,--,--,100.00,Yes
Evaluation or Interview for Risk of Opioid Misuse,414,Registry/QCDR,Process,Y,58.16 - 91.73,91.74 - 98.30,98.31 - 99.52,99.53 - 99.99,--,--,--,100.00,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Registry/QCDR,Efficiency,Y,58.18 - 67.85,67.86 - 76.46,76.47 - 85.18,85.19 - 93.55,93.56 - 97.51,97.52 - 98.80,98.81 - 99.99,100.00,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,415,Claims,Efficiency,Y,85.19 - 93.32,93.33 - 96.14,96.15 - 99.99,--,--,--,--,100.00,Yes
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years,416,Registry/QCDR,Efficiency,Y,40.82 - 33.56,33.55 - 27.74,27.73 - 22.60,22.59 - 15.64,15.63 - 9.39,9.38 - 3.93,3.92 - 1.46,<= 1.45,No
Osteoporosis Management in Women Who Had a Fracture,418,Registry/QCDR,Process,Y,2.04 - 2.93,2.94 - 3.69,3.7 - 4.83,4.84 - 9.51,9.52 - 18.45,18.46 - 31.31,31.32 - 45.82,>= 45.83,No
Overuse of Imaging for the Evaluation of Primary Headache,419,Registry/QCDR,Process,Y,76.19 - 81.91,81.9 - 86.90,86.89 - 89.81,89.8 - 92.60,92.59 - 94.72,94.71 - 96.44,96.43 - 99.99,100.00,No
Perioperative Anti-platelet Therapy for Patients Undergoing Carotid Endarterectomy,423,Registry/QCDR,Process,Y,93.94 - 96.14,96.15 - 99.78,99.79 - 99.99,--,--,--,--,100.00,No
Perioperative Temperature Management,424,Registry/QCDR,Outcome,Y,91.69 - 97.66,97.67 - 99.42,99.43 - 99.73,99.74 - 99.85,99.86 - 99.94,99.95 - 99.99,--,100.00,Yes
Photodocumentation of Cecal Intubation,425,Registry/QCDR,Process,Y,95.78 - 97.71,97.72 - 98.40,98.41 - 98.79,98.8 - 99.17,99.18 - 99.38,99.39 - 99.61,99.62 - 99.90,>= 99.91,Yes
Photodocumentation of Cecal Intubation,425,Claims,Process,Y,93.55 - 98.17,98.18 - 99.04,99.05 - 99.49,99.5 - 99.99,--,--,--,100.00,Yes
Post-Anesthetic Transfer of Care Measure: Procedure Room to a Post Anesthesia Care Unit (PACU),426,Registry/QCDR,Process,Y,94.09 - 99.15,99.16 - 99.77,99.78 - 99.91,99.92 - 99.98,99.99 - 99.99,--,--,100.00,Yes
Post-Anesthetic Transfer of Care: Use of Checklist or Protocol for Direct Transfer of Care from Procedure Room to Intensive Care Unit (ICU),427,Registry/QCDR,Process,Y,83.78 - 94.89,94.9 - 97.36,97.37 - 98.75,98.76 - 99.49,99.5 - 99.99,--,--,100.00,Yes
Prevention of Post-Operative Nausea and Vomiting (PONV) - Combination Therapy,430,Registry/QCDR,Process,Y,87.8 - 94.69,94.7 - 97.29,97.3 - 98.57,98.58 - 99.26,99.27 - 99.66,99.67 - 99.88,99.89 - 99.99,100.00,Yes
Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling,431,Registry/QCDR,Process,Y,11.22 - 35.59,35.6 - 52.48,52.49 - 69.33,69.34 - 81.57,81.58 - 89.87,89.88 - 95.09,95.1 - 98.74,>= 98.75,No
Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair,432,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,No
Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair,433,Registry/QCDR,Outcome,Y,0.45 - 0.01,--,--,--,--,--,--,0.00,No
Quality of Life Assessment For Patients With Primary Headache Disorders,435,Registry/QCDR,PatientReportedOutcome,Y,3.13 - 4.75,4.76 - 14.28,14.29 - 36.83,36.84 - 49.08,49.09 - 80.55,80.56 - 99.99,--,100.00,No
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Registry/QCDR,Process,Y,85.14 - 96.86,96.87 - 99.07,99.08 - 99.69,99.7 - 99.92,99.93 - 99.99,--,--,100.00,Yes
Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques,436,Claims,Process,Y,90.17 - 97.40,97.41 - 99.07,99.08 - 99.67,99.68 - 99.89,99.9 - 99.99,--,--,100.00,Yes
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Claims,Outcome,Y,2.94 - 2.09,2.08 - 1.86,1.85 - 1.09,1.08 - 0.01,--,--,--,0.00,Yes
Rate of Surgical Conversion from Lower Extremity Endovascular Revascularization Procedure,437,Registry/QCDR,Outcome,Y,7.36 - 2.87,2.86 - 0.01,--,--,--,--,--,0.00,Yes
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,EHR,Process,Y,42.18 - 57.13,57.14 - 63.19,63.2 - 66.84,66.85 - 69.82,69.83 - 72.95,72.96 - 75.58,75.59 - 78.56,>= 78.57,Yes
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease,438,Registry/QCDR,Process,Y,64.16 - 72.87,72.88 - 78.87,78.88 - 85.62,85.63 - 91.66,91.67 - 95.23,95.24 - 99.59,99.6 - 99.99,100.00,Yes
Age Appropriate Screening Colonoscopy,439,Registry/QCDR,Efficiency,Y,36.84 - 0.64,0.63 - 0.01,--,--,--,--,--,0.00,No
Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time - Pathologist to Clinician,440,Registry/QCDR,Process,Y,91.93 - 98.71,98.72 - 99.61,99.62 - 99.99,--,--,--,--,100.00,Yes
Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control),441,Registry/QCDR,IntermediateOutcome,Y,20.64 - 36.94,36.95 - 45.52,45.53 - 52.77,52.78 - 58.97,58.98 - 63.63,63.64 - 66.89,66.9 - 71.82,>= 71.83,No
Non-Recommended Cervical Cancer Screening in Adolescent Females,443,Registry/QCDR,Process,Y,3.68 - 2.75,2.74 - 1.93,1.92 - 1.73,1.72 - 0.01,--,--,--,0.00,No
Medication Management for People with Asthma,444,Registry/QCDR,Process,Y,55.33 - 73.70,73.71 - 80.33,80.34 - 91.29,91.3 - 96.66,96.67 - 99.99,--,--,100.00,Yes
Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG),445,Registry/QCDR,Outcome,Y,5.56 - 3.18,3.17 - 2.82,2.81 - 2.34,2.33 - 1.88,1.87 - 1.40,1.39 - 1.03,1.02 - 0.01,0.00,No
HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies,449,Registry/QCDR,Process,Y,89.29 - 93.47,93.48 - 97.68,97.69 - 98.86,98.87 - 99.99,--,--,--,100.00,Yes
Percentage of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score - better),453,Registry/QCDR,Process,Y,20.0 - 17.29,17.28 - 14.30,14.29 - 12.01,12.0 - 10.01,10.0 - 8.83,8.82 - 7.01,7.0 - 5.46,<= 5.45,No
Percentage of Patients Who Died From Cancer Not Admitted To Hospice (lower score - better),456,Registry/QCDR,Process,Y,93.22 - 84.01,84.0 - 77.28,77.27 - 75.61,75.6 - 68.34,68.33 - 64.53,64.52 - 60.69,60.68 - 54.56,<= 54.55,No
Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days (lower score - better),457,Registry/QCDR,Outcome,Y,18.9 - 15.83,15.82 - 14.49,14.48 - 12.32,12.31 - 10.01,10.0 - 8.56,8.55 - 6.71,6.7 - 4.78,<= 4.77,No
Prevention of Post-Operative Vomiting (POV) - Combination Therapy (Pediatrics),463,Registry/QCDR,Process,Y,91.18 - 94.81,94.82 - 96.31,96.32 - 97.85,97.86 - 98.56,98.57 - 99.17,99.18 - 99.73,99.74 - 99.99,100.00,No
Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use,464,Registry/QCDR,Process,Y,80.0 - 86.72,86.73 - 89.00,89.01 - 92.00,92.01 - 94.80,94.81 - 96.04,96.05 - 97.70,97.71 - 99.99,100.00,No
Psoriasis: Assessment of Psoriasis Disease Activity,AAD1,Registry/QCDR,Process,Y,6.74 - 13.45,13.46 - 28.29,28.3 - 45.17,45.18 - 60.32,60.33 - 72.76,72.77 - 84.04,84.05 - 90.11,>= 90.12,No
Psoriasis: Screening for Psoriatic Arthritis,AAD2,Registry/QCDR,Process,Y,6.64 - 15.93,15.94 - 36.17,36.18 - 59.73,59.74 - 78.19,78.2 - 85.35,85.36 - 91.85,91.86 - 98.77,>= 98.78,Yes
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients,AAD3,Registry/QCDR,Process,Y,6.15 - 4.01,4.0 - 1.81,1.8 - 0.01,--,--,--,--,0.00,Yes
Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk,AAD4,Registry/QCDR,Process,Y,11.11 - 3.17,3.16 - 1.40,1.39 - 0.01,--,--,--,--,0.00,No
Biopsy: Reporting Time - Clinician to Patient,AAD5,Registry/QCDR,Process,Y,82.93 - 95.64,95.65 - 98.30,98.31 - 99.99,--,--,--,--,100.00,Yes
Diabetes/Pre-Diabetes Screening for Patients with DSP,AAN1,Registry/QCDR,Process,Y,4.35 - 9.42,9.43 - 11.10,11.11 - 17.85,17.86 - 20.50,20.51 - 22.40,22.41 - 35.28,35.29 - 63.15,>= 63.16,No
Falls screening (aggregation of AAN disease specific falls measures),AAN10,Registry/QCDR,Process,Y,2.01 - 3.80,3.81 - 6.57,6.58 - 9.43,9.44 - 15.25,15.26 - 19.81,19.82 - 33.98,33.99 - 41.18,>= 41.19,No
Screening for Psychiatric or Behavioral Health Disorders,AAN4,Registry/QCDR,Process,Y,23.48 - 31.24,31.25 - 43.47,43.48 - 62.29,62.3 - 81.89,81.9 - 89.13,89.14 - 94.80,94.81 - 98.41,>= 98.42,No
Medication Prescribed For Acute Migraine Attack,AAN5,Registry/QCDR,Process,Y,39.73 - 47.48,47.49 - 56.92,56.93 - 61.24,61.25 - 65.62,65.63 - 69.85,69.86 - 73.36,73.37 - 77.77,>= 77.78,No
Exercise and Appropriate Physical Activity Counseling for Patients with MS,AAN8,Registry/QCDR,Process,Y,38.41 - 47.47,47.48 - 62.62,62.63 - 73.40,73.41 - 78.44,78.45 - 87.49,87.5 - 91.88,91.89 - 95.93,>= 95.94,No
Querying About Symptoms of Autonomic Dysfunction for Patients with Parkinson's Disease,AAN9,Registry/QCDR,Process,Y,3.13 - 13.20,13.21 - 35.47,35.48 - 53.65,53.66 - 78.66,78.67 - 87.99,88.0 - 92.58,92.59 - 95.55,>= 95.56,No
Otitis Media with Effusion: Avoidance of Topical Intranasal Corticosteroids,AAO11,Registry/QCDR,Process,Y,99.23 - 99.69,99.7 - 99.99,--,--,--,--,--,100.00,Yes
Percentage of patients with cerumen impaction and a suggestive history of a non-intact tympanic membrane who receive just manual removal.,AAO15,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,No
Age-related Hearing Loss: Advanced Diagnostic Imaging of Bilateral Presbycusis or Symmetric SNHL,AAO17,Registry/QCDR,Process,Y,97.59 - 98.50,98.51 - 98.83,98.84 - 99.37,99.38 - 99.99,--,--,--,100.00,No
Percentage of patients with allergic rhinitis who do not receive sinonasal imaging for allergic rhinitis,AAO22,Registry/QCDR,Process,Y,92.7 - 95.11,95.12 - 96.72,96.73 - 97.69,97.7 - 98.54,98.55 - 99.69,99.7 - 99.99,--,100.00,No
Allergic Rhinitis: Intranasal Corticosteroids or Oral Antihistamines,AAO23,Registry/QCDR,Process,Y,47.1 - 62.78,62.79 - 67.55,67.56 - 70.49,70.5 - 74.54,74.55 - 75.64,75.65 - 78.52,78.53 - 83.19,>= 83.2,No
Allergic Rhinitis: Avoidance of Leukotriene Inhibitors,AAO24,Registry/QCDR,Process,Y,87.66 - 91.52,91.53 - 93.13,93.14 - 95.47,95.48 - 96.56,96.57 - 97.16,97.17 - 98.13,98.14 - 98.74,>= 98.75,No
Percentage of patients with allergic rhinitis who do not receive IgG-based immunoglobulin testing,AAO25,Registry/QCDR,Process,Y,99.94 - 99.99,--,--,--,--,--,--,100.00,No
Otitis Media with Effusion: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility,AAO26,Registry/QCDR,Process,Y,4.76 - 40.49,40.5 - 49.56,49.57 - 53.32,53.33 - 65.63,65.64 - 74.28,74.29 - 79.12,79.13 - 81.43,>= 81.44,No
Tympanostomy Tubes: Resolution of Otitis Media with Effusion in Adults,AAO28,Registry/QCDR,Outcome,Y,5.0 - 9.99,10.0 - 12.11,12.12 - 15.90,15.91 - 18.93,18.94 - 21.80,21.81 - 26.91,26.92 - 38.70,>= 38.71,No
Otitis Media with Effusion: Antihistamines or Decongestants – Avoidance of Inappropriate Use,AAO8,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,Yes
Intra-operative anesthesia safety,ABG1,Registry/QCDR,Outcome,Y,99.81 - 99.89,99.9 - 99.95,99.96 - 99.99,--,--,--,--,100.00,Yes
Planned use of difficult airway equipment,ABG16,Registry/QCDR,Process,Y,29.49 - 43.98,43.99 - 63.32,63.33 - 73.16,73.17 - 80.22,80.23 - 84.41,84.42 - 90.69,90.7 - 93.29,>= 93.3,No
Pre-operative OSA assessment,ABG21,Registry/QCDR,Process,Y,69.61 - 85.54,85.55 - 92.78,92.79 - 96.72,96.73 - 99.07,99.08 - 99.91,99.92 - 99.99,--,100.00,No
Pre-Operative Screening for GERD,ABG28,Registry/QCDR,Process,Y,68.08 - 81.99,82.0 - 93.21,93.22 - 97.59,97.6 - 99.76,99.77 - 99.99,--,--,100.00,No
Pre-Operative Screening for Glaucoma,ABG29,Registry/QCDR,Process,Y,33.65 - 57.50,57.51 - 73.56,73.57 - 85.35,85.36 - 93.75,93.76 - 99.74,99.75 - 99.99,--,100.00,Yes
Pre-Operative Screening for PONV Risk,ABG30,Registry/QCDR,Process,Y,10.49 - 40.79,40.8 - 73.11,73.12 - 99.74,99.75 - 99.94,99.95 - 99.99,--,--,100.00,Yes
Pre-Operative Screening for Excessive Alcohol and Recreational Drug Use,ABG31,Registry/QCDR,Process,Y,56.98 - 72.57,72.58 - 84.61,84.62 - 93.01,93.02 - 99.91,99.92 - 99.99,--,--,100.00,Yes
Corneal Abrasion,ABG36,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,0.00,No
Immediate Adult Post-Operative Pain Management,ABG7,Registry/QCDR,Outcome,Y,97.63 - 98.89,98.9 - 99.49,99.5 - 99.75,99.76 - 99.86,99.87 - 99.94,99.95 - 99.99,--,100.00,Yes
ACCPin3 Heart Failure: Patient Self Care Education,ACCPIN3,Registry/QCDR,Process,Y,8.51 - 41.91,41.92 - 62.21,62.22 - 76.22,76.23 - 85.70,85.71 - 88.80,88.81 - 92.58,92.59 - 95.24,>= 95.25,Yes
Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older,ACEP19,Registry/QCDR,Process,Y,50.45 - 53.86,53.87 - 54.77,54.78 - 57.76,57.77 - 59.78,59.79 - 62.88,62.89 - 68.12,68.13 - 74.07,>= 74.08,No
Coagulation Studies in Patients Presenting with Chest Pain with No Coagulopathy or Bleeding,ACEP21,Registry/QCDR,Process,Y,19.29 - 14.68,14.67 - 13.41,13.4 - 9.59,9.58 - 8.39,8.38 - 6.07,6.06 - 5.10,5.09 - 3.92,<= 3.91,No
Pregnancy Test for Female Abdominal Pain Patients,ACEP24,Registry/QCDR,Process,Y,69.7 - 74.62,74.63 - 77.21,77.22 - 79.77,79.78 - 81.94,81.95 - 83.16,83.17 - 85.99,86.0 - 88.56,>= 88.57,No
Tobacco Use:  Screening and Cessation Intervention for Patients with Asthma and COPD,ACEP25,Registry/QCDR,Process,Y,35.52 - 43.96,43.97 - 50.94,50.95 - 59.37,59.38 - 62.25,62.26 - 65.75,65.76 - 69.40,69.41 - 76.80,>= 76.81,No
Sepsis Management: Septic Shock: Repeat Lactate Level Measurement,ACEP29,Registry/QCDR,Process,Y,63.27 - 72.85,72.86 - 78.25,78.26 - 84.90,84.91 - 87.22,87.23 - 89.28,89.29 - 90.62,90.63 - 92.67,>= 92.68,No
Sepsis Management: Septic Shock: Lactate Clearance Rate of >= 10%,ACEP30,Registry/QCDR,Outcome,Y,68.56 - 70.31,70.32 - 72.54,72.55 - 73.67,73.68 - 76.43,76.44 - 77.56,77.57 - 80.94,80.95 - 82.21,>= 82.22,No
Appropriate Foley catheter use in the emergency department,ACEP31,Registry/QCDR,Process,Y,63.27 - 81.81,81.82 - 84.05,84.06 - 87.24,87.25 - 91.01,91.02 - 97.66,97.67 - 99.67,99.68 - 99.99,100.00,No
ED Median Time from ED arrival to ED departure for discharged ED patients for Adult Patients,ACEP32,Registry/QCDR,Outcome,Y,281.0 - 212.01,212.0 - 189.01,189.0 - 177.01,177.0 - 169.01,169.0 - 158.01,158.0 - 148.01,148.0 - 140.01,<= 140.0,No
ED Median Time from ED arrival to ED departure for discharged ED patients for Pediatric Patients,ACEP40,Registry/QCDR,Outcome,Y,196.0 - 151.01,151.0 - 135.51,135.5 - 128.01,128.0 - 118.01,118.0 - 114.01,114.0 - 108.51,108.5 - 99.01,<= 99.0,No
"Sepsis Management: Septic Shock: Lactate Level Measurement, Antibiotics Ordered, and Fluid Resuscitation",ACEP48,Registry/QCDR,Process,Y,60.0 - 68.36,68.37 - 74.35,74.36 - 77.26,77.27 - 81.79,81.8 - 84.84,84.85 - 86.59,86.6 - 88.70,>= 88.71,No
COPD Exacerbation: % of patients discharged from inpatient status on Long Acting Beta Agonist (LABA) bronchodilator,ACQR2,Registry/QCDR,Process,Y,91.3 - 94.34,94.35 - 94.91,94.92 - 95.16,95.17 - 95.84,95.85 - 96.14,96.15 - 96.82,96.83 - 97.60,>= 97.61,No
COPD: Steroids for no more than 5 days in COPD Exacerbation,ACQR3,Registry/QCDR,Efficiency,Y,86.25 - 88.13,88.14 - 89.07,89.08 - 90.96,90.97 - 92.66,92.67 - 93.65,93.66 - 93.74,93.75 - 95.39,>= 95.4,No
CHF: Document AHA/ACC staging of CHF (A-D),ACQR5,Registry/QCDR,Process,Y,67.28 - 77.11,77.12 - 80.64,80.65 - 81.62,81.63 - 83.70,83.71 - 85.79,85.8 - 87.14,87.15 - 90.41,>= 90.42,No
Stroke/TIA: % of patients discharged on antithrombotic therapy,ACQR8,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,No
Gout: Serum Urate Target,ACR7,Registry/QCDR,IntermediateOutcome,Y,24.19 - 35.70,35.71 - 45.30,45.31 - 49.99,50.0 - 55.43,55.44 - 59.99,60.0 - 63.32,63.33 - 69.33,>= 69.34,No
Report Turnaround Time: Radiography,ACRAD15,Registry/QCDR,Outcome,Y,53.0 - 8.01,8.0 - 4.01,4.0 - 2.01,2.0 - 2.01,2.0 - 1.01,1.0 - 1.01,1.0 - 0.01,0.00,No
Report Turnaround Time: Ultrasound (Excluding Breast US),ACRAD16,Registry/QCDR,Outcome,Y,82.0 - 6.01,6.0 - 4.01,4.0 - 3.01,3.0 - 2.01,2.0 - 1.01,1.0 - 1.01,1.0 - 1.01,<= 1.0,No
Report Turnaround Time: MRI,ACRAD17,Registry/QCDR,Outcome,Y,111.0 - 15.01,15.0 - 9.01,9.0 - 7.01,7.0 - 6.01,6.0 - 5.01,5.0 - 4.01,4.0 - 3.01,<= 3.0,No
Report Turnaround Time: CT,ACRAD18,Registry/QCDR,Outcome,Y,37.0 - 6.01,6.0 - 3.01,3.0 - 2.01,2.0 - 1.01,1.0 - 1.01,1.0 - 1.01,1.0 - 0.01,0.00,No
Report Turnaround Time: PET,ACRAD19,Registry/QCDR,Outcome,Y,111.0 - 43.01,43.0 - 25.01,25.0 - 19.01,19.0 - 16.01,16.0 - 8.51,8.5 - 6.01,6.0 - 4.01,<= 4.0,No
Lung Cancer Screening Abnormal Interpretation Rate,ACRAD23,Registry/QCDR,Outcome,Y,25.24 - 21.45,21.44 - 18.16,18.15 - 17.14,17.13 - 15.70,15.69 - 14.15,14.14 - 12.51,12.5 - 11.43,<= 11.42,No
Report Turnaround Time: Mammography,ACRAD25,Registry/QCDR,Outcome,Y,1573.0 - 50.01,50.0 - 33.01,33.0 - 20.01,20.0 - 15.01,15.0 - 11.01,11.0 - 8.01,8.0 - 5.01,<= 5.0,No
Screening Mammography Cancer Detection Rate (CDR),ACRAD3,Registry/QCDR,Outcome,Y,0.22 - 0.30,0.31 - 0.34,0.35 - 0.40,0.41 - 0.43,0.44 - 0.48,0.49 - 0.54,0.55 - 0.56,>= 0.57,No
Percent of CT Abdomen-pelvis exams with contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD31,Registry/QCDR,Outcome,Y,59.36 - 72.35,72.36 - 80.96,80.97 - 86.43,86.44 - 87.14,87.15 - 87.14,87.15 - 92.56,92.57 - 96.28,>= 96.29,Yes
Percent of CT Chest exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level.,ACRAD32,Registry/QCDR,Outcome,Y,70.52 - 73.88,73.89 - 75.82,75.83 - 76.34,76.35 - 84.80,84.81 - 88.01,88.02 - 95.37,95.38 - 98.74,>= 98.75,Yes
Percent of CT Head/Brain exams without contrast (single phase scan) for which Dose Length Product is at or below the size-specific diagnostic reference level,ACRAD33,Registry/QCDR,Outcome,Y,30.73 - 30.72,30.73 - 61.20,61.21 - 75.71,75.72 - 80.39,80.4 - 91.12,91.13 - 93.62,93.63 - 97.52,>= 97.53,Yes
Screening Mammography Abnormal Interpretation Rate (Recall Rate),ACRAD5,Registry/QCDR,Outcome,Y,14.91 - 12.96,12.95 - 10.31,10.3 - 8.97,8.96 - 8.62,8.61 - 7.67,7.66 - 5.98,5.97 - 4.24,<= 4.23,No
Screening Mammography Positive Predictive Value 2 (PPV2 - Biopsy Recommended),ACRAD6,Registry/QCDR,Outcome,Y,17.32 - 21.83,21.84 - 23.88,23.89 - 24.73,24.74 - 27.30,27.31 - 28.98,28.99 - 30.55,30.56 - 32.07,>= 32.08,No
Patient-Reported Experience with Anesthesia,AQI48,Registry/QCDR,Outcome,Y,91.07 - 92.32,92.33 - 93.21,93.22 - 94.20,94.21 - 94.94,94.95 - 95.55,95.56 - 95.94,95.95 - 96.68,>= 96.69,Yes
Application of Lung-Protective Ventilation during General Anesthesia,AQI50,Registry/QCDR,IntermediateOutcome,Y,98.96 - 99.49,99.5 - 99.71,99.72 - 99.85,99.86 - 99.99,--,--,--,100.00,Yes
Assessment of Patients for Obstructive Sleep Apnea,AQI51,Registry/QCDR,Process,Y,39.23 - 79.14,79.15 - 90.55,90.56 - 95.89,95.9 - 99.11,99.12 - 99.78,99.79 - 99.97,99.98 - 99.99,100.00,Yes
Documentation of Anticoagulant and Antiplatelet Medications when Performing Neuraxial Anesthesia/Analgesia or Interventional Pain Procedures,AQI53,Registry/QCDR,Process,Y,56.25 - 74.00,74.01 - 76.86,76.87 - 94.45,94.46 - 98.07,98.08 - 99.99,--,--,100.00,No
Use of Pencil-Point Needle for Spinal Anesthesia,AQI54,Registry/QCDR,Process,Y,90.22 - 97.43,97.44 - 98.52,98.53 - 99.36,99.37 - 99.80,99.81 - 99.99,--,--,100.00,No
Use of Neuraxial Techniques and/or Peripheral Nerve Blocks for Total Knee Arthroplasty (TKA),AQI56,Registry/QCDR,Process,Y,72.61 - 91.71,91.72 - 94.74,94.75 - 96.48,96.49 - 98.15,98.16 - 98.58,98.59 - 99.84,99.85 - 99.99,100.00,No
Multimodal Pain Management,AQI59,Registry/QCDR,Process,Y,69.14 - 80.46,80.47 - 85.11,85.12 - 89.44,89.45 - 92.75,92.76 - 95.87,95.88 - 97.71,97.72 - 99.68,>= 99.69,No
New Corneal Injury Not Diagnosed Prior to Discharge,AQI60,Registry/QCDR,Outcome,Y,99.87 - 99.93,99.94 - 99.97,99.98 - 99.98,99.99 - 99.99,--,--,--,100.00,No
Stones: Urinalysis documented 30 days before surgical stone procedures,AQUA15,Registry/QCDR,Process,Y,34.55 - 52.45,52.46 - 65.56,65.57 - 72.72,72.73 - 76.85,76.86 - 82.22,82.23 - 85.96,85.97 - 88.61,>= 88.62,No
Non-Muscle Invasive Bladder Cancer: Early surveillance cystoscopy within 4 months of initial diagnosis,AQUA18,Registry/QCDR,Process,Y,78.05 - 80.76,80.77 - 88.13,88.14 - 91.47,91.48 - 93.93,93.94 - 96.29,96.3 - 99.99,--,100.00,No
Benign Prostate Hyperplasia Care: Benign Prostate Hyperplasia,AQUA26,Registry/QCDR,Process,Y,16.45 - 10.07,10.06 - 8.74,8.73 - 7.37,7.36 - 6.83,6.82 - 5.17,5.16 - 3.48,3.47 - 3.02,<= 3.01,No
Hospital admissions/complications within 30 days of TRUS Biopsy,AQUA8,Registry/QCDR,Outcome,Y,6.77 - 4.75,4.74 - 2.62,2.61 - 1.69,1.68 - 0.01,--,--,--,0.00,Yes
Surgeon assessment for hereditary cause of breast cancer,ASBS1,Registry/QCDR,Process,Y,95.93 - 98.74,98.75 - 99.99,--,--,--,--,--,100.00,Yes
Return to the operating room for re-excision of previous microscopically negative margins in invasive breast cancer patients undergoing breast conserving therapy,ASBS12,Registry/QCDR,Outcome,Y,96.12 - 98.14,98.15 - 99.99,--,--,--,--,--,100.00,No
Unplanned 30 day re-operation after mastectomy,ASBS7,Registry/QCDR,Outcome,Y,95.0 - 95.64,95.65 - 98.35,98.36 - 98.74,98.75 - 99.99,--,--,--,100.00,Yes
Avoid Head CT for Patients with Uncomplicated Syncope,ECPR39,Registry/QCDR,Process,Y,95.83 - 97.43,97.44 - 99.06,99.07 - 99.76,99.77 - 99.99,--,--,--,100.00,No
Avoidance of Creatine Kinase-MB (CK-MB) Testing for Non-traumatic Chest Pain,ECPR45,Registry/QCDR,Process,Y,77.89 - 91.32,91.33 - 96.94,96.95 - 97.13,97.14 - 98.16,98.17 - 99.06,99.07 - 99.32,99.33 - 99.56,>= 99.57,No
Appropriate management of anticoagulation in the peri-procedural period rate - EGD,GIQIC10,Registry/QCDR,Process,Y,23.33 - 53.32,53.33 - 72.78,72.79 - 86.14,86.15 - 94.68,94.69 - 97.72,97.73 - 99.99,--,100.00,No
Appropriate indication for colonoscopy,GIQIC12,Registry/QCDR,Process,Y,76.2 - 83.66,83.67 - 86.43,86.44 - 89.30,89.31 - 91.04,91.05 - 92.87,92.88 - 94.51,94.52 - 96.30,>= 96.31,No
Appropriate follow-up interval of 3 years recommended based on pathology findings from screening colonoscopy in average-risk patients,GIQIC15,Registry/QCDR,Process,Y,54.24 - 64.57,64.58 - 73.07,73.08 - 78.94,78.95 - 82.60,82.61 - 85.47,85.48 - 87.99,88.0 - 91.22,>= 91.23,No
Appropriate follow-up interval of 5 years for colonoscopies with findings of sessile serrated polyps < 10 mm without dysplasia,GIQIC17,Registry/QCDR,Process,Y,71.23 - 79.99,80.0 - 84.61,84.62 - 86.35,86.36 - 90.47,90.48 - 93.74,93.75 - 95.64,95.65 - 97.49,>= 97.5,No
Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm,GIQIC18,Registry/QCDR,Process,Y,83.13 - 89.28,89.29 - 92.30,92.31 - 94.99,95.0 - 97.09,97.1 - 97.91,97.92 - 99.23,99.24 - 99.99,100.00,No
Appropriate indication for esophagogastroduodenoscopy (EGD),GIQIC19,Registry/QCDR,Process,Y,26.88 - 34.12,34.13 - 41.85,41.86 - 49.10,49.11 - 60.09,60.1 - 68.35,68.36 - 83.56,83.57 - 92.84,>= 92.85,No
Appropriate follow-up interval of 10 years for colonoscopies with only hyperplastic polyp findings,GIQIC20,Registry/QCDR,Process,Y,25.0 - 70.89,70.9 - 80.53,80.54 - 86.83,86.84 - 91.29,91.3 - 95.17,95.18 - 96.96,96.97 - 99.99,100.00,No
"Hypogonadism: Serum T, CBC, PSA, IPSS within 6  months of Rx",IQSS1,Registry/QCDR,Process,Y,1.09 - 1.58,1.59 - 2.62,2.63 - 3.02,3.03 - 3.69,3.7 - 5.40,5.41 - 6.24,6.25 - 8.32,>= 8.33,No
"Prostate Cancer: Newly diagnosed with documented T stage, PSA score, and Gleason score",IQSS2,Registry/QCDR,Process,Y,1.21 - 2.24,2.25 - 3.05,3.06 - 3.67,3.68 - 4.75,4.76 - 4.99,5.0 - 8.51,8.52 - 12.63,>= 12.64,No
Prostate Cancer: Treatment Options Counseling,IQSS3,Registry/QCDR,Process,Y,56.0 - 68.72,68.73 - 75.89,75.9 - 80.59,80.6 - 83.99,84.0 - 90.90,90.91 - 93.25,93.26 - 95.77,>= 95.78,No
BPH: Anticholinergics,IQSS4,Registry/QCDR,Process,Y,25.76 - 39.57,39.58 - 52.37,52.38 - 59.99,60.0 - 63.99,64.0 - 67.99,68.0 - 72.72,72.73 - 79.54,>= 79.55,No
Endothelial Keratoplasty - Post-operative improvement in best corrected visual acuity to 20/40 or better,IRIS1,Registry/QCDR,Outcome,Y,9.52 - 22.72,22.73 - 32.07,32.08 - 37.03,37.04 - 50.71,50.72 - 53.96,53.97 - 57.99,58.0 - 74.99,>= 75.0,No
Exudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS10,Registry/QCDR,Outcome,Y,--,--,--,--,--,--,--,100.00,No
Nonexudative Age-Related Macular Degeneration - Loss of Visual Acuity,IRIS11,Registry/QCDR,Outcome,Y,80.13 - 86.20,86.21 - 88.79,88.8 - 90.69,90.7 - 92.54,92.55 - 93.93,93.94 - 95.29,95.3 - 96.54,>= 96.55,No
Diabetic Macular Edema - Loss of Visual Acuity,IRIS13,Registry/QCDR,Outcome,Y,73.68 - 79.34,79.35 - 83.32,83.33 - 86.93,86.94 - 89.17,89.18 - 90.47,90.48 - 91.83,91.84 - 93.74,>= 93.75,No
Acute Anterior Uveitis - Post-treatment visual acuity,IRIS16,Registry/QCDR,Outcome,Y,86.67 - 91.29,91.3 - 93.82,93.83 - 95.23,95.24 - 95.97,95.98 - 96.96,96.97 - 98.49,98.5 - 99.99,100.00,No
Acute Anterior Uveitis - Post-treatment Grade 0 anterior chamber cells,IRIS17,Registry/QCDR,Outcome,Y,19.23 - 32.13,32.14 - 46.31,46.32 - 54.99,55.0 - 63.32,63.33 - 69.56,69.57 - 74.31,74.32 - 81.81,>= 81.82,No
Glaucoma - Intraocular Pressure (IOP) Reduction,IRIS2,Registry/QCDR,IntermediateOutcome,Y,51.59 - 69.77,69.78 - 78.78,78.79 - 84.64,84.65 - 88.88,88.89 - 91.52,91.53 - 93.58,93.59 - 95.31,>= 95.32,Yes
Refractive Surgery:  Patients with a postoperative uncorrected visual acuity (UCVA) of 20/20 or better,IRIS23,Registry/QCDR,Outcome,Y,19.02 - 45.89,45.9 - 54.99,55.0 - 65.21,65.22 - 75.48,75.49 - 81.57,81.58 - 87.68,87.69 - 94.86,>= 94.87,No
Adenoviral Conjunctivitis:  Avoidance of Antibiotics,IRIS25,Registry/QCDR,Efficiency,Y,37.5 - 16.68,16.67 - 7.15,7.14 - 2.79,2.78 - 0.01,--,--,--,0.00,No
Intravitreal Injections: Avoidance of Routine Antibiotic Use,IRIS26,Registry/QCDR,Efficiency,Y,5.45 - 3.04,3.03 - 1.58,1.57 - 0.61,0.6 - 0.01,--,--,--,0.00,No
Complications After Cataract Surgery,IRIS27,Registry/QCDR,Outcome,Y,1.57 - 0.65,0.64 - 0.22,0.21 - 0.01,--,--,--,--,0.00,No
Regaining Vision After Cataract Surgery,IRIS28,Registry/QCDR,Outcome,Y,20.61 - 31.06,31.07 - 37.98,37.99 - 44.64,44.65 - 51.04,51.05 - 56.71,56.72 - 62.65,62.66 - 69.77,>= 69.78,No
Improved visual acuity after epiretinal membrane treatment within 90 days,IRIS29,Registry/QCDR,Outcome,Y,15.38 - 19.60,19.61 - 20.82,20.83 - 27.77,27.78 - 31.57,31.58 - 32.90,32.91 - 34.37,34.38 - 49.99,>= 50.0,No
Glaucoma - Visual Field Progression,IRIS3,Registry/QCDR,Outcome,Y,20.67 - 17.15,17.14 - 14.40,14.39 - 12.01,12.0 - 9.20,9.19 - 7.15,7.14 - 5.33,5.32 - 4.01,<= 4.0,No
Return to OR within 90 days after epiretinal membrane surgical treatment,IRIS30,Registry/QCDR,Outcome,Y,1.2 - 0.01,--,--,--,--,--,--,0.00,No
Avoidance of Genetic Testing for Age-related Macular Degeneration,IRIS31,Registry/QCDR,Efficiency,Y,--,--,--,--,--,--,--,0.00,No
Return to OR within 90 days after macular hole surgery,IRIS33,Registry/QCDR,Outcome,Y,5.26 - 2.03,2.02 - 0.01,--,--,--,--,--,0.00,No
Age-Related Macular Degeneration: Disease Progression,IRIS34,Registry/QCDR,Outcome,Y,6.52 - 4.30,4.29 - 2.89,2.88 - 1.86,1.85 - 0.78,0.77 - 0.01,--,--,0.00,No
Glaucoma - Intraocular Pressure Reduction Following Laser Trabeculoplasty,IRIS4,Registry/QCDR,Outcome,Y,13.48 - 18.24,18.25 - 23.80,23.81 - 27.26,27.27 - 30.98,30.99 - 34.93,34.94 - 39.01,39.02 - 43.32,>= 43.33,No
Amblyopia - Interocular Visual Acuity,IRIS7,Registry/QCDR,Outcome,Y,16.13 - 20.82,20.83 - 26.91,26.92 - 29.79,29.8 - 32.13,32.14 - 33.32,33.33 - 35.18,35.19 - 37.19,>= 37.2,No
Diabetic Retinopathy - Documentation of the Presence or Absence of Macular Edema and the Level of Severity of Retinopathy,IRIS9,Registry/QCDR,Process,Y,--,--,--,--,--,--,--,100.00,No
M2S 1: Procedures with statin and antiplatelet agents prescribed at discharge,M2S1,Registry/QCDR,Process,Y,62.16 - 71.42,71.43 - 77.49,77.5 - 80.94,80.95 - 82.97,82.98 - 85.99,86.0 - 86.35,86.36 - 88.88,>= 88.89,No
Case Delay,MA1,Registry/QCDR,Efficiency,Y,12.16 - 9.63,9.62 - 6.78,6.77 - 4.38,4.37 - 3.18,3.17 - 2.35,2.34 - 1.12,1.11 - 0.49,<= 0.48,No
Risk standardized rate of patients who experienced a postoperative escalation in care event following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP10,Registry/QCDR,Outcome,Y,8.45 - 7.90,7.89 - 6.91,6.9 - 5.01,5.0 - 3.94,3.93 - 3.09,3.08 - 2.18,2.17 - 1.62,<= 1.61,No
Risk standardized rate of patients who experienced a pulmonary complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy,MBSAQIP11,Registry/QCDR,Outcome,Y,2.63 - 1.91,1.9 - 1.42,1.41 - 1.01,1.0 - 0.25,0.24 - 0.01,--,--,0.00,No
Risk standardized rate of patients who experienced a postoperative complication following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP12,Registry/QCDR,Outcome,Y,4.0 - 3.34,3.33 - 2.51,2.5 - 2.28,2.27 - 1.46,1.45 - 1.10,1.09 - 0.98,0.97 - 0.01,0.00,No
"Risk standardized rate of patients who experienced postoperative nausea, vomiting or fluid/electrolyte/nutritional depletion following a primary Laparoscopic Roux-en-Y Gastric Bypass or Laparoscopic Sleeve Gastrectomy operation",MBSAQIP7,Registry/QCDR,Outcome,Y,2.74 - 2.31,2.3 - 2.18,2.17 - 1.55,1.54 - 0.69,0.68 - 0.48,0.47 - 0.01,--,0.00,Yes
Risk standardized rate of patients who experienced an extended length of stay (> 3 days) following a primary Laparoscopic Roux-en-Y Gastric Bypass or  Laparoscopic Sleeve Gastrectomy operation,MBSAQIP8,Registry/QCDR,Outcome,Y,5.0 - 3.34,3.33 - 2.83,2.82 - 1.92,1.91 - 1.56,1.55 - 1.16,1.15 - 1.06,1.05 - 0.49,<= 0.48,Yes
Heel Pain Treatment Outcomes for Adults,MEX1,Registry/QCDR,Outcome,Y,2.26 - 11.99,12.0 - 23.89,23.9 - 37.28,37.29 - 46.80,46.81 - 57.24,57.25 - 66.09,66.1 - 74.99,>= 75.0,No
Bunion Outcome - Adult and Adolescent,MEX4,Registry/QCDR,Outcome,Y,1.96 - 4.02,4.03 - 6.82,6.83 - 12.45,12.46 - 18.87,18.88 - 23.46,23.47 - 31.21,31.22 - 41.79,>= 41.8,No
Hammer Toe Outcome,MEX5,Registry/QCDR,Outcome,Y,1.69 - 2.85,2.86 - 7.88,7.89 - 10.33,10.34 - 15.37,15.38 - 18.59,18.6 - 27.26,27.27 - 45.70,>= 45.71,No
Rate of witnessed gastric aspiration,MIRAMED17,Registry/QCDR,Outcome,Y,0.41 - 0.27,0.26 - 0.17,0.16 - 0.13,0.12 - 0.11,0.1 - 0.09,0.08 - 0.07,0.06 - 0.03,<= 0.02,No
Unplanned Conversion to General Anesthesia from Regional or MAC for all scheduled cases,MIRAMED18,Registry/QCDR,Process,Y,96.78 - 98.18,98.19 - 98.36,98.37 - 98.95,98.96 - 99.29,99.3 - 99.71,99.72 - 99.82,99.83 - 99.92,>= 99.93,No
Onset atrial fibrillation or dysrhythmia requiring unanticipated therapy,MIRAMED19,Registry/QCDR,Outcome,Y,0.47 - 0.31,0.3 - 0.20,0.19 - 0.15,0.14 - 0.12,0.11 - 0.10,0.09 - 0.09,0.08 - 0.05,<= 0.04,No
Medicare Spending Per Beneficiary (MSPB),MSPB_1,AdministrativeClaims,,Y,43284.0 - 24418.01,24418.0 - 23155.01,23155.0 - 22358.01,22358.0 - 21726.01,21726.0 - 21180.01,21180.0 - 20670.01,20670.0 - 20136.01,<= 20136.0,No
Prostate Biopsy Antibiotic Compliance,MUSIC1,Registry/QCDR,Process,Y,99.35 - 99.99,--,--,--,--,--,--,100.00,Yes
Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months,MUSIC11,Registry/QCDR,Process,Y,4.55 - 5.12,5.13 - 7.68,7.69 - 9.51,9.52 - 12.36,12.37 - 15.99,16.0 - 20.06,20.07 - 26.08,>= 26.09,No
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,Registry/QCDR,Process,Y,7.69 - 15.99,16.0 - 20.88,20.89 - 29.50,29.51 - 39.28,39.29 - 49.99,50.0 - 63.40,63.41 - 74.90,>= 74.91,No
AVOIDING EXCESSIVE USE OF EPIDURAL INJECTIONS IN MANAGING CHRONIC PAIN ORIGINATING IN THE CERVICAL AND THORACIC SPINE,NIPM8,Registry/QCDR,Efficiency,Y,99.2 - 99.60,99.61 - 99.99,--,--,--,--,--,100.00,No
AVOIDING EXCESSIVE USE OF THERAPEUTIC FACET JOINT INTERVENTIONS IN MANAGING CHRONIC CERVICAL AND THORACIC SPINAL PAIN,NIPM9,Registry/QCDR,Efficiency,Y,--,--,--,--,--,--,--,100.00,No
Unplanned Admission to Hospital Following Percutaneous Spine Procedure within the 30-Day Post-procedure Period,NPAGSC9,Registry/QCDR,Outcome,Y,28.15 - 19.32,19.31 - 2.71,2.7 - 0.01,--,--,--,--,0.00,No
Advance Care Planning in Stage 4 Disease,PIMSH1,Registry/QCDR,PatientEngagementExperience,Y,0.65 - 1.39,1.4 - 2.79,2.8 - 9.00,9.01 - 20.95,20.96 - 34.30,34.31 - 43.43,43.44 - 58.32,>= 58.33,No
Utilization of GCSF in Metastatic Colon Cancer,PIMSH2,Registry/QCDR,Process,Y,57.14 - 36.06,36.05 - 30.44,30.43 - 27.51,27.5 - 24.15,24.14 - 22.01,22.0 - 16.91,16.9 - 13.44,<= 13.43,No
Central Line Ultrasound Guidance,QUANTUM31,Registry/QCDR,Process,Y,55.26 - 78.54,78.55 - 92.75,92.76 - 95.35,95.36 - 98.44,98.45 - 99.30,99.31 - 99.99,--,100.00,No
Upper Extremity Edema Improvement,RCOIR10,Registry/QCDR,Outcome,Y,36.62 - 48.18,48.19 - 52.26,52.27 - 56.62,56.63 - 60.92,60.93 - 67.73,67.74 - 73.07,73.08 - 74.99,>= 75.0,No
Improved Access Site Bleeding,RCOIR7,Registry/QCDR,Outcome,Y,48.28 - 53.72,53.73 - 62.66,62.67 - 68.17,68.18 - 73.45,73.46 - 75.75,75.76 - 83.18,83.19 - 86.41,>= 86.42,No
Post Procedure Bleeding,RCOIR8,Registry/QCDR,Outcome,Y,0.3 - 0.25,0.24 - 0.20,0.19 - 0.12,0.11 - 0.09,0.08 - 0.01,--,--,0.00,No
Hospitalization Rate Following Procedures Performed under Procedure Sedation Analgesia,RPAQIR11,Registry/QCDR,Outcome,Y,0.77 - 0.48,0.47 - 0.37,0.36 - 0.24,0.23 - 0.18,0.17 - 0.13,0.12 - 0.01,--,0.00,Yes
Arterial Complication Rate Following Arteriovenous Access Intervention,RPAQIR12,Registry/QCDR,Outcome,Y,0.81 - 0.48,0.47 - 0.38,0.37 - 0.25,0.24 - 0.17,0.16 - 0.12,0.11 - 0.07,0.06 - 0.01,0.00,Yes
Rate of Timely Documentation Transmission to Dialysis Unit/Referring Physician,RPAQIR13,Registry/QCDR,Process,Y,69.09 - 75.36,75.37 - 79.18,79.19 - 82.21,82.22 - 83.79,83.8 - 85.06,85.07 - 87.93,87.94 - 89.02,>= 89.03,Yes
Prolonged Length of Stay Following Coronary Artery Bypass Grafting,STS1,Registry/QCDR,Outcome,Y,9.3 - 7.70,7.69 - 5.98,5.97 - 4.65,4.64 - 3.71,3.7 - 3.34,3.33 - 2.36,2.35 - 1.83,<= 1.82,No
Prolonged Length of Stay for Coronary Artery Bypass Grafting (CABG) + Valve Replacement,STS3,Registry/QCDR,Outcome,Y,13.64 - 10.72,10.71 - 10.01,10.0 - 8.34,8.33 - 7.61,7.6 - 5.14,5.13 - 4.56,4.55 - 3.46,<= 3.45,Yes
Prolonged Length of Stay following Valve Surgery,STS5,Registry/QCDR,Outcome,Y,12.3 - 9.03,9.02 - 7.07,7.06 - 6.62,6.61 - 5.12,5.11 - 3.74,3.73 - 2.85,2.84 - 2.00,<= 1.99,No
Patient Centered Surgical Risk Assessment and Communication for Cardiac Surgery,STS7,Registry/QCDR,Process,Y,1.96 - 3.56,3.57 - 12.87,12.88 - 34.75,34.76 - 56.51,56.52 - 77.47,77.48 - 89.28,89.29 - 96.45,>= 96.46,No
Total Per Capita Costs (TPCC),TPCC_1,AdministrativeClaims,,Y,79929.9 - 18838.76,18838.75 - 15754.41,15754.4 - 14355.01,14355.0 - 13447.81,13447.8 - 12712.16,12712.15 - 11998.91,11998.9 - 11197.01,<= 11197.0,No
Controlled Gout for Patients on Urate-Lowering Pharmacologic Therapy,UREQA3,Registry/QCDR,IntermediateOutcome,Y,45.1 - 55.23,55.24 - 57.93,57.94 - 62.75,62.76 - 65.21,65.22 - 66.41,66.42 - 67.85,67.86 - 71.18,>= 71.19,No
Folic or Folinic Acid Therapy for Patients Treated with Methotrexate,UREQA4,Registry/QCDR,Process,Y,69.77 - 78.09,78.1 - 85.33,85.34 - 90.57,90.58 - 93.29,93.3 - 94.30,94.31 - 94.96,94.97 - 96.82,>= 96.83,No
UR006 - Regular Evaluation of Psoriatic Arthritis (PsA),UREQA5,Registry/QCDR,Process,Y,6.17 - 7.75,7.76 - 10.33,10.34 - 12.12,12.13 - 15.14,15.15 - 17.86,17.87 - 24.35,24.36 - 28.24,>= 28.25,No
